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ABSTRACT 
Genomic instability in South African breast cancer patients 
B.C. Langa, Degree of Magister Scientiae (MSc) Thesis, Department of Medical 
Biosciences, University of the Western Cape 
Breast cancer (BC) is one of the most common malignancies in women. Death results 
from treatment failure and metastatic disease.  Thousands of lives might be saved if it 
was possible to detect and eliminate occult metastatic cells before they become 
clinically evident.  Therefore, there is a critical need to identify new markers to 
improve treatment options for these patients. 
Genomic instability is the earliest indication of breast cancer and the use of genomic 
methodologies is a progress towards early detection and treatment, through the 
identification of biomarkers that can be translated into novel therapy targets.  
The interferon regulatory factor-1(IRF-1) gene, localized on chromosome 5q31.1, is 
believed to act as a tumor suppressor gene in breast cancer.  The IRF-1 was found to 
be inactivated by single nucleotide polymorphism (SNP) in breast cancer suggesting 
that the loss of its function might be critical to the development of the disease. 
The phosphatidylinositol 3-kinase (PIK3) signaling pathway mediates key cellular 
functions and alterations of genes in this pathway, including PIK3CA, serine-threonine 
protein kinases (AKT1and AKT2), phosphatase and tensin homolog (PTEN), fibroblast 
growth factor receptor 2 (FGFR2) and ERBB2, whose expression have been 
demonstrated to be altered in breast cancer patients.  In addition, these genes are 
linked to treatment resistance. 
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In this study, we have investigated allelic loss of IRF-1 gene in primary tumors 
obtained from patients undergoing mastectomy at Groote Schuur hospital (Cape 
Town, South Africa).  These samples were then further analyzed for the DNA copy 
number changes of specific genes involved in the PIK3/AKT signaling pathway. 
Statistical analysis has been performed in order to correlate genomic findings with 
clinical-histopathological and follow up information from the patients and to establish 
whether these genes can predict prognosis. 
Our data analysis has indicated that 46 cases (45.5%) out of 101 cases were 
informative for the IRF-1 dinucleotide marker used for LOH analysis (Figure 3.1). 
LOH was detected in 23 of these informative cases (23/46; 50%).  No statistical 
significance was found between LOH at the IRF-1 locus and age (≤50 years or >50 
years) (P value = 1.0000) and earlier stage (Stages I and II) (P value= 0.4982) based 
on Fisher’s exact test.  
Patients presented a high level of DNA copy number changes in genes involved in the 
PIK3/AKT pathway.  The most frequent changes were observed in the PIK3CA and 
PTEN genes.  PIK3CA presented high copy number in 36.8% of the cases. PTEN was 
observed with low copy number in 47.5% of the cases. 
This dissertation shows the effectiveness of genomic methodologies as means for the 
detection of early breast cancer progression in South African women.  The PIK 3/AKT 
genes can validate the usefulness of breast cancer therapies.  
Keywords: Breast cancer, primary tumors, loss of heterozygosity, genomic 
instability, the interferon regulator factor 1, the phosphatidyl inositol kinase 
pathway. 
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CHAPTER 1 
THE LITERATURE REVIEW 
1.1 Background 
Breast cancer is one of the most common and potentially lethal diseases in 
women worldwide (Parkin, Pisani et al. 1999; Boyle, Leon et al. 2003).  Differences 
in incidence and mortality in different populations and different regions of the world 
strongly indicate that the disease is multi factorial and both environmental and genetic 
factors are implicated (Cullen, Maguire et al. 2001; Nathanson, Wooster et al. 2001).  
Extensive research into the aetiology and pathobiology of breast cancer continues 
apace while other investigators are working on improving the detection methods.  
With reference to the latter, it is evident that the current detection techniques lack the 
desired sensitivity and specificity needed to ensure the early detection and ultimate 
survival of most cases of breast cancer and ultimately improve the survival (Tabar, 
Yen et al. 2003). 
The breast consists of the mammary gland and associated skin and connective 
tissues.  The mammary gland consists of a series of ducts and associated secretory 
lobules.  These converge to form 15 to 20 lactiferous ducts, which open independently 
onto the nipple.  The breast lies on deep fascia over pectoralis major muscle.  With 
such anatomical location, it is related both to the thoracic wall as well as the structures 
associated with the upper limb; therefore the arterial supply, venous drainage as well 
as the lymphatic drainage occurs via multiple routes.  The breast receives its blood 
supply from branches of the axillary, internal thoracic and intercostal arteries.  Veins 
draining the breast parallel the arteries and ultimately drain into the axillary, internal 
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thoracic and intercostal veins.  The lymph drainage of the breast is amazingly 
extensive; most of the lymphatic drainage occurs through the axillary nodes that 
receive approximately 75% of the lymphatic vessels.  The supraclavicular, parasternal 
and abdominal lymph nodes as well as the opposite breast receive the remaining 
drainage (Richard 2009). 
Breast disorders are very common and present mainly as benign or malignant 
breast lumps.  Benign breast lumps are common in patients in the younger age group 
and can result from benign proliferations of either the glandular tissue, the ductal 
system or its fibrous surroundings.  Histopathological and immunohistochemical 
examination of primary breast tumors has provided substantial evidence that breast 
cancer cells are epithelial in origin,  originating either from the mammary lobules or 
ducts (Stevens, Lowe et al. 2002).  Although evidence suggest that the growth and 
spread of these tumors usually depends on the exact cellular site of origin of the 
cancer, it is a known fact that metastatic breast cancer cells lodge mainly in the 
axillary lymph nodes.  However, the extensive lymphatic drainage which may cause 
parallel spread of malignancy to other nodal groups makes the management of 
advanced breast cancer potentially difficult and eventually leads to treatment failure 
and death (O'Higgins, Linos et al. 1998). 
Once a lump is detected, either by self examination, clinical examination, or 
screening, the next step is to establish whether such lump is malignant or not.  This 
confirmation is accomplished by a biopsy followed by histopathological evaluation of 
the specimen.  Generally, most breast lumps should be removed surgically and sent 
for pathological evaluation.  If malignancy is confirmed, the next step is to attempt at 
finding whether metastatic cells have lodged in the regional lymph nodes .  The search 
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for malignant cells will be then complemented by the search for metastases in organs 
most likely to harbour metastases like the lungs, liver and bones.  This might be 
achieved via several detection means such as conducting hematological and 
radiological tests (Weis and Cheresh 2011). 
Once this evaluation is complete the surgeon and the pathologist will be able 
to stage the tumor.  In an attempt to achieve unity in describing solid tumors, the 
international union against cancer (UICC) has established a system that serves as a 
global language for the classification of solid tumors (Hermanek 1999).  The system 
was called the TNM which stands for Tumor-Node-Metastasis.  This system has been 
in existence for more than 50 years.  It is based on measuring the size of the primary 
tumor, determining the number and the group of regional nodes involved and 
detecting the involvement of distant sites.  Subsequently, these three variables will be 
assigned to four stages (I-IV) that describe the severity of the disease and help in 
defining the optimal treatment choices as well as providing a preliminary idea about 
the prognosis (Sobin, Hermanek et al. 1988).  
The surgical management of breast cancer has evolved dramatically over the 
past century. In the beginning of the century, Halsted (1907) proposed that cancer 
progression followed a sequential pattern, and thus  recommended the use of 
extensive radical surgery to cure it, as it was considered as a local-regional disease  
(Halsted 1907).  The original procedure included removal of the breast and the  
underlying muscle together with an axillary nodal clearance.  Such an invasive 
procedure was associated with many complications and slow recovery.  Disappointed 
by the fact that radical mastectomy did not cure all the patients, other surgeons have 
reported their experience with less invasive surgical procedures and tried the 
preservation of the axillary nodes (Haffty, McKhann et al. 1993; Guenther, Hansen et 
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al. 2003).  In an attempt to summarize the surgical approach in that period, Fisher 
(1999) has stated that “ Most of the period from 1900 to 1970 was governed by the 
‘non-science’ of anecdotalism and clinical inductivism and was marked by the 
absence of science gestalt”.  Consequently, the shift in the paradigm of surgical 
intervention has appeared gradually, driven by the results of randomized clinical trials 
which have compared various techniques.  For example, two of these trials were 
conducted by Fisher and co workers between 1971 to 1985.  They reported that a 15 
year follow-up of 2000 women who were randomly distributed among three treatment 
groups: total mastectomy, lumpectomy alone or lumpectomy followed by breast 
irradiation indicating that there was no difference in disease free- survival or overall 
survival rates.  Meta-analyses of trials indicate equivalence of survival when various 
surgical techniques are compared.  Thus, the current approach would be to perform a 
mastectomy for larger tumors, and wide local excision with radiotherapy for smaller 
ones, should these choices be acceptable to the patient (Fisher 1999).  
The decision on whether to remove or preserve the axillary lymph nodes that 
are apparently free of clinically identifiable metastatic disease has changed over the 
years.  When the tumor is smaller than two centimeters and the lymph nodes are not 
palpable, the initial surgical approach was to preserve the axillary nodes and 
complement the treatment with local radiation since the disease was initially thought 
to be locoregional (Dubois 1990).  However, of concern was the report by Fisher et al 
(1983) in which it was stated that  in 30% of women with node-negative axilla who 
underwent only mastectomy without lymphatic clearance, metastatic disease recurred 
within 5 years and eventually the woman died of it (Fisher, Bauer et al. 1983).  
Subsequently, other researchers have confirmed the importance of such observation.  
Of these was the report of Rosner et.al (1993) who have conducted a10-year follow-
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up on 407 breast cancer patients that were treated by surgery alone reporting a 10-year 
recurrence rate of 19% (Rosner and Lane 1993).  In addition, a recent report by Fodor 
et al (2005) after a 15 year follow-up, have stated that a relapse rate of 24% has been 
found in 92 breast cancer patients who had undergone mastectomy with nodal 
preservation and 75% relapse rate in 56 breast cancer patients who had only their 
primary tumor been removed.  This clinical manifestation of distant relapse implies 
that these patients already developed sub clinical occult micro-metastases at the time 
of primary tumor excision and therefore the decision of preservation of axillary 
content is not necessarily a good decision (Fodor, Mozsa et al. 2005). 
The above reports imply that as a precautionary measure, removal of the 
axillary lymph nodes should be carried out in each case.  However, surgical 
experiences have revealed that complete nodal dissection is not without 
complications, since there is a high morbidity where many of the patients suffer from 
post mastectomy lymphedema.  For example, Petrek et.al (2001) have shown that 
49% of the 263 patients that had had complete nodal dissection developed 
lymphedema.  For this reason, the search for methods to improve the detection of 
metastases while at the same time sparing the axillary contents became a necessity 
(Petrek, Senie et al. 2001).  
Researchers reasoned that if metastasis had occurred, tumor cells might be 
detected in other areas of the body.  Therefore, investigators begun to sample other 
areas such as blood and bone marrow (Domschke, Ge et al. 2013).  Braun et.al (2000) 
have obtained bone marrow aspirates from both upper iliac crests of 552 patients with 
stage I, II, or III breast cancer and 191 patients with nonmalignant disease.  The 
specimens were stained with the monoclonal antibody A45-B/B3, which binds to an 
 
 
 
 
6 
 
antigen on cytokeratins.  The group has reported a detection rate of 36% (Braun, 
Pantel et al. 2000).  Furthermore, Ballestrero et.al (2001) have studied the specificity 
of maspin mRNA marker when used in a nested polymerase chain reaction (PCR) 
assay to detect breast cancer micro-metastasis in the bone marrow.  The marker was 
expressed in all the 41 breast cancer patients but also in 40% of the 17 patients with 
hematological malignancies other than breast cancer stating that the marker is not 
disease specific (Ballestrero, Coviello et al. 2001). Lin, Zhang et.al (2000) have tried 
sampling the blood and using a combination of 4 monoclonal antibodies (BM7, BM8 
against MUC1, 5D3 against CK8,18,19 and HEA125 against human epithelial 
antigen) and a sensitive immunocytochemical staining  procedure to identify breast 
cancer cells in leukapheresis products.  However, their assay detection rate has not 
exceeded 20%.  It has become evident after such studies that malignant cells are 
present in low concentrations in such samples which have made the attention to be 
redirected again towards examining the nodal basin (Lin, Zhong et al. 2000). 
Sentinel lymph node biopsy (SLNB) has been introduced as an alternative 
method for evaluation of the lymphatic basin with further aim of proceeding with 
complete axillary lymph node dissection if the sentinel node has been found to contain 
metastases (Kiricuta 2000).  The sentinel node was originally defined as the first node 
to receive lymphatic flow from a primary tumor.  Subsequently, this definition has 
been revised as it has been found that in many instances, parallel lymphatic channels 
from the primary tumor drain to more than one node making such definition 
applicable to more than one node.  To overcome such debate, the general surgical 
trend if more than one sentinel node can be detected at the time of surgical operation, 
is to remove all these nodes.  In such cases the true sentinel node will be the node that 
contains metastatic cells.  However, other nodes in same basins will not contain these 
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metastatic cells (Nathanson 1999).  The development of sentinel node surgery has 
helped the pathologists to provide a more focused analysis.  However, the extensive 
pathological work that has been dedicated towards improving the detection of 
metastases lacked standardization.  This fact became evident when studies attempting 
to compare such results were confounded by the lack of consistency and subsequently, 
the prognostic impact of such micro-metastases remained questionable (Cserni 2004).  
However, a very recent randomized clinical trial has shown that patients with 
limited sentinel lymph node metastastatic breast cancer treated with breast 
conservation and systemic therapy, the use of SLNB did not result in inferior survival 
(Giuliano, Hunt et al. 2011).  In addition, a 10-year follow up of treatment outcomes 
in patients with early breast cancer and negative axillary lymph nodes that were 
treated with tangential breast irradiation following sentinel lymph node dissection or 
axillary lymph node dissection concluded that the conservative approach yielded a 
similar prognostic results (Wernicke, Goodman et al. 2011). 
1.2 The history of BC cancer detection in South Africa 
The following sections provide an insight with regard to the history of BC 
cancer detection in South Africa.  A revision of the development of various molecular 
methods for optimal detection of genomic instability in patients with breast cancer has 
been included in this chapter. 
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1.2.1 Breast Cancer in South African Women: An updated report with an insight 
into Triple negative breast Cancer 
In South Africa, this cancer follows similar worldwide statistics (Parkin, Sitas 
et al. 2008). National Cancer Registry (2013) shows that Breast Cancer is top of the 
list in South African females.  A report on the cancer incidence in a rural population 
of South Africa has shown that breast cancer is the third common cancer after cancer 
of the cervix and oesophageal cancer.  It was also documented that African women 
demonstrated a lower age of occurrence (35-40 years) when compared to other 
women globally (Somdyala, Bradshaw et al. 2010).  
There are several known risk factors for BC in the African continent.  BC risk 
is mainly attributed to menstrual and reproductive factors like the age at menarche, 
parity, and breast feeding and these vary according to the social class/status 
(Henderson, Ross et al. 1982) .  In addition, obesity plays a major role as African 
women are known to have high body mass index (BMI) (Goedecke, Evans et al. 
2011).  Life style factors like high alcohol consumption, low physical exercise levels, 
and exposure to exogenous hormones either as contraceptives or postmenopausal 
hormone replacement therapy.  However, these finding warrant further research in 
Africa (McCurtis Witherspoon and Williams Richardson 2006).  
Among other risk factors, race seems to be an important determinant for the 
lifetime risks of developing breast cancer.  Vorobiof et.al (2001) has shown that black 
women are less affected than white women and women of mixed ancestry..  
Moreover, a recent report has indicated that breast cancer incidence ranges from a low 
occurrence of one in 81 in African women (similar to Japan) to as high as one in 13 
among white women, similar to rates in Western countries (Vorobiof, Sitas et al. 
 
 
 
 
9 
 
2001).  However, the myth of being a “disease of the white” has changed over the 
years (Helman 1977; Bradshaw and Harington 1982).  It was documented that African 
black women with breast cancer have started to show an increasing incidence and tend 
to have a low survival rate.  In 1984, Walker et al. reported on the poor survival of 
females affected by breast cancer but failed to indicate a possible aetiology (Walker, 
Walker et al. 1984; Walker, Adam et al. 2004).  In addition, a report by Fregene et.al 
(2005) has indicated that the mortality rates are strikingly high among African women 
despite their low breast cancer incidence rate when compared to Western populations 
(Fregene and Newman 2005).  Other reports have stressed on the fact that the disease 
is usually detected at its late stages (Stage III and IV) (Hassan, Onukak et al. 1992; 
Muguti 1993; Amir, Kitinya et al. 1994; Amir, Azizi et al. 1997).  In addition the 
tumor grade and tendency for proliferation was reported to be higher in African 
women (Fregene and Newman 2005).  
The high mortality in the Black African women might be attributed to several 
ongoing problems that are particular to the African continent.  One of the most 
apparent problems is the lack of awareness of breast cancer which tend to be low on 
the list of health care priorities.  A 2002 report has documented that 25% of urban 
South African women and 33% of rural women would seek the advice of a traditional 
healer when it comes to breast lumps (Pillay 2002).  A second concern might be the 
access to breast cancer screening; as it was documented that rural black women have 
less access to screening than those living an urban life.  This lack of medical services 
provision in South African women might be attributed to the socioeconomic status 
and other competing life threats like HIV/AIDS and tuberculosis (Brown and 
Williams 1994).  All this have led to the fact that breast cancer is not detected at its 
early stages in the black community.  It is beyond doubt that the early detection might 
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help in reducing mortality rate and improve survival in black women (Chu, Tarone et 
al. 1996). 
Moreover, the validity of screening methods for the early detection of breast 
cancer has been questioned, despite the fact that early detection of breast cancer 
improves the therapeutic outcome (Meng, Ward et al. 2011).  Recent studies have 
questioned the efficacy of conventional detection methods such as mammography and 
self-testing; self-testing has proven to have little to no effect on mortality rates 
(Thomas, Carter et al. 2002).  On the other hand, mammography results in lower 
mortality rates in the population at large, but in young women the false positive rate 
results in a large number of unnecessary biopsies (Berry, Cronin et al. 2005). 
Therefore, the need has arisen to find other means for early detection of breast cancer.  
The molecular screening of patients offers an accurate complimentary 
alternative to mammography.  Unfortunately, despite the advance in molecular 
methodologies, the genetic profiles associated with breast cancer in Africa remains 
poorly investigated.  This is attributed mainly to the cost of such studies and the lack 
of proper documentation of patients clinical data (Basro and Apffelstaedt 2010).  
However, in the last two decades, several studies have tried to unravel the molecular 
event associated with breast cancer (Sjogren, Inganas et al. 1996; Hilakivi-Clarke, 
Wang et al. 2004; Fisher, Cole et al. 2010). 
In addition, Ameyaw, Thornton et.al (2000) discovered that the over- 
expression of protooncogene Her2/ neu which is reported in 15-30% of breast cancers 
was also studied in African women; blood from 200 Ghanaian , 257 Caucasian and 90 
African American healthy women was genotyped.  The known single nucleotide 
polymorphism (Val655Ile) which is associated with an aggressive phenotype was not 
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found in the African specimens, but it was found in 20% of the Caucasians and 24% 
of the African-Americans recruited for the study (Ameyaw, Thornton et al. 2000). 
However, in the last few years, two interesting articles have emerged.  The 
first study done by Reeves et.al (2004) has reported on the role of BRCA1 in South 
African breast and/or ovarian cancer families.  A total of 90 South African 
breast/ovarian cancer families were screened for BRCA1 mutations by means of PCR-
based mutation detection assays.  Eighteen families (20%) were identified with 
BRCA1 disease-causing mutations.  Four Ashkenazi Jewish families were identified 
with the 185delAG mutation, whereas 2 Afrikaner and 1 Ashkenazi Jewish family 
were found to harbor the 5382insC mutation.  Five of the families (5.56%), all of 
whom are Afrikaners, were found to carry the novel E881X mutation.  Genotype 
analyses show that these patients share a common ancestor.  Genealogic studies have 
identified 3 possible founding couples for this mutation, all of whom arrived in the 
Cape from France in the late 1600s.  Of the remaining mutations detected, 3 have not 
been reported previously and include the S451X, 1493delC and 4957insC mutations 
(Reeves, Yawitch et al. 2004).  A consecutive study has recruited 105 Coloured and 
16 Black Xhosa women residing in the Western Cape of South Africa diagnosed with 
breast cancer.  These patients were screened using a panel of six previously reported 
SA Afrikaner and Ashkenazi Jewish BRCA1/2 mutations and identified only two 
Afrikaner mutations. In addition, screening by the protein truncation test (BRCA1 
exon 11, and BRCA2 exons 10 and 11) revealed an additional four deleterious 
mutations(BRCA1c.1504_1508del,p.Leu502AlafsX2,BRCA2c.2826_2829del,p.Ile94
3LysfsX16,c.6447_6448dup,p.Lys2150IlefsX19 and c.5771_5774del,p.Ile1924Argfs 
X38).  The latter, also known in Breast Cancer Information Core nomenclature as 
5999del4, was identified in 4 of 105 (3.8%) Coloureds and 4 of 16 (25%) Xhosa 
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women, which makes it a frequent  mutation in the Western Cape Province.  Despite 
the fact that the previous study has reported that this mutation occurs in the 
Netherlands, haplotype analysis indicated two distinct origins for the Dutch and South 
African mutations, excluding the possibility of a common Dutch ancestor and 
suggesting gene flow from the indigenous tribes such as the Xhosa to the Coloured 
population instead (van der Merwe, Hamel et al. 2012).  Currently, these mutations 
are linked to the triple negative phenotype breast cancer.  The reasons for these 
associations are unclear but may ultimately provide avenues for prevention and 
targeted therapy (Irvin and Carey 2008). 
It is well-known that when the cancer is discovered early, patients live longer 
and require less extensive treatment (Lurie and Parker 2007).  For the previously 
mentioned reasons, treatment options were limited, most of these women were 
exposed to mastectomy and its post-operative complications due to the advanced stage 
of the disease where breast conservation was not an option (McNeely, Binkley et al. 
2012).  
1.3 Triple Negative Breast Cancer (TNBC) 
1.3.1 Is TNBC common in South Africa? Research attempts to sub-classify 
TNBC cases 
Until recently, the hormone receptor status was not investigated in most parts 
of Sub-Saharan Africa simply because of the lack of technology, therefore, many 
women were treated blindly with Tamoxifen, the known hormonal treatment for 
breast cancer, and this approach was acceptable somehow because of the minimum 
side effects (Clegg-Lamptey, Dakubo et al. 2009).  Subsequently, several groups of 
researchers have started to report on these receptors’ absence and worked towards 
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finding better histological sub-types of these tumors with the further aim of finding 
means of alternative treatment approaches and gaining a better insight regarding the 
disease prognosis (El Khouli, Macura et al. 2009). 
Within the last decade, the concept of triple negative breast cancer (TNBC) 
was introduced and refers to approximately 10–15% of breast carcinomas . TNBC is 
defined as a subtype that lacks the expression of oestrogen receptor (ER), 
progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2). 
The treatment of these tumors is challenging because there is no specific target for 
hormonal treatment.  However and despite the fact that TNBC exhibits poor response 
to hormonal treatment, many reports have indicated that such tumors display 
increased chemo sensitivity when compared with other breast tumor subtypes 
(Chavez, Garimella et al. 2010). 
In order to refine the choice of treatment, there was a need to define the 
heterogeneity of TNBC.  Several ongoing studies are trying to characterize these 
tumors at the molecular level.  Studies based on the proliferation-related marker Ki 67 
have shown that at least two subgroups exist within TNBC, each with a different 
response to chemotherapy and ultimately they varied in prognosis (Giuffre, Adamo et 
al. 2011). 
Researchers have initiated immunohistochemical studies in an attempt to get a 
better means of classifying patients and finding means for treatment.  Initially, studies 
based on basal immunohistochemical markers (epidermal growth factor receptor type 
1 (EGFR) and cytokeratin 5/6 have shown that at least two subgroups exsist (Giuffre, 
Adamo et al. 2011).  More recent studies like the report by van Bogaert (2013) have 
identified 6 molecular subtypes of TNBC using immunohistochemistry.  These were 
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the Luminal A(ER+/PR+, HER2-), luminal B(ER+/PR+, HER2+), triple negative 
(ER-/PR-, HER2-), basal like(ER-/PR-, HER2-, CK5/6+), null type (ER-/PR-, HER2-, 
CK5/6-) and tumors that over express HER2 which are usually associated with poor 
prognosis.  He concluded that there is a commonality between the various subtypes 
among African-American and women in sub-Saharan Africa (van Bogaert 2013). 
Another study has reported a similar classification  depending on the gene expression 
profiling of 587 TNBC cases (Lehmann, Bauer et al. 2011). 
It was reported that TNBC has a worse prognosis and tends to relapse early 
compared with other subtypes of breast cancer (Dawood 2010).  Several prognostic 
markers were studied to get an insight about the prognosis.  Of these the Ki-67 was 
studied and its high level is associated with favourable prognosis (Nishimura, Osako 
et al. 2010) .  Furthermore, gene expression studies have classified TNBC into two 
main subtypes, claudin low and basal like with no major prognostic difference.  The 
latter have been found to have higher percentage and is associated with P53 
mutations.  In addition, the overlap between TNBC and BRCA1 and BRCA2 
mutations was also reported.  These tumors are reported to have a favourable 
prognosis.  This heterogeneity in classification made comparison between different 
reports difficult and warranted further studies (Perou 2010). 
 
1.4 Pathological and Clinical characteristics of TNBC 
Research within the pathology department worldwide has attempted to find 
clear pathological stratification on the basis of the difference in gene expression 
profile Five major groups were characterised as follows: the first two groups are 
called Luminal A and B and were ER positive.  The remaining three were ER 
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negative and grouped as follows: A“Basal-like breast cancer characterised by the lack 
of expression of ER, PgR and HER-2 as well as incresead expression of basal 
cytokeratins CKs 5/6 and 17.  The second type is erbB2 like/HER-2 like with high 
expression of erb2 and thirdly the normal like BC showing molecular charecteristics 
of normal tissue (Sorlie, Perou et al. 2001). 
Most TNBC have demonstrated a very aggressive phenotype with almost 80% 
clinical and pathological overlap with BRCA1 and basal-like subtype of BC.  It is 
documented that more than 90% of TNBC demonstrate an invasive ductal histology, 
with high mitotic index, central necrotic zones and pushing borders as well as 
lymphocytic infilterate (Gluz, Liedtke et al. 2009). 
Clinically, most TNBC patients have an early onset of presentation.  However, 
a team has reported on the detection of TNBC in older women which contradict the 
fact of favourable prognosis being associated with late presentations and calls for the 
need of more serious interventions in the older age group (Aapro and Wildiers 2012) . 
The mortality associated with TNBC is alarming in women of African descent. 
Metastases happen within the first three years of treatment.  In addition, the 5-year 
survival rate is much lower when compared with other types of breast cancer.  Thus 
there is a continuous search for early detection-markers of prognostic significance that 
might help in improving the prognosis (Boyle 2012). 
The fact that these tumors do not respond to the known hormonal treatment 
like Tamoxifen and Trustazumab had led to the search for novel therapeutic targets.  
Several agents are currently being investigated as potential therapeutic agents for the 
treatment of women with TNBC including agents targeted against epidermal growth 
factor receptor EGFR, poly (ADP-ribose) polymerase (PARP) inhibitors, anti-
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angiogenic agents, and multityrosine kinase inhibitors showing promising results 
(Anders and Carey 2008; Rottenberg, Jaspers et al. 2008).  
 
1.5 Methodologies to identify molecular markers of early changes. 
1.5.1 Genomic instability as a means for early detection of breast cancer 
It is known that breast cancer exhibits a heterogenous behaviour with regard to 
metastatic potential and response to treatment (Silva, Dominguez et al. 1999).  
Accumulating body of evidence has shown that the study of early genetic alterations 
in tumor cells seems to help in identifying markers of prognostic significance. 
Advances in methodology have allowed us to more precisely determine the 
approximate chronology of some of these aberrations and the possible roles each 
plays in the formation of malignancy.  It is now proposed that the early loss of cell 
cycle control in the presence of a mitogenic stimulus allows a cell to divide 
unchecked.  Such uncontrolled proliferation would yield a high level of genomic 
instability.  As proliferation continues, numerous additional chromosomal 
abnormalities occur, and increased tumor heterogeneity would be observed as distinct 
subpopulations emerge in the evolution toward a progressively more aggressive 
phenotype.  However, much still remains to be learned to gain a full understanding of 
the key players behind the genetic evolution of breast cancer.  This can be only 
achieved by analyzing the pre-invasive and putative early stages of breast cancer in 
order to characterize the most probable sequence of genomic abnormalities (Brenner 
and Aldaz 1997). 
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Two methods for the detection of changes in the DNA of tumor cells have 
been explored in this study. 
1.6 Loss of heterzygosity/allelic instability in patients with BC: 
The allelic losses at particular chromosome regions are common (Isaacs, 
Cavalli et al. 2004).  These losses might indicate deletion in the second allele of a 
tumor suppressor gene.  However, this phenomenon might be due to other 
mechanisms associated with these deletion like aberrant somatic recombinations and 
mitotic nondisjunction (Murthy, DiFrancesco et al. 2002).  The allelic instability has 
been investigated in patients with TNBC.  A study has analysed 22 common breast 
cancer susceptibility variants in 2,980 Caucasian women with triple-negative breast 
cancer and 4,978 healthy controls.  The team had identified six single-nucleotide 
polymorphisms, including rs2046210 (ESR1), rs12662670 (ESR1), rs3803662 
(TOX3), rs999737 (RAD51L1), rs8170 (19p13.1), and rs8100241 (19p13.1), these 
were significantly associated with the risk of triple-negative breast cancer (Stevens, 
Fredericksen et al. 2012).  
The detection of LOH in DNA material obtained from ductal lavage (DL) and 
nipple aspirate fluid (NAF) in BC patients have generated promising data.  A goup 
have studied 26 DL and 6 NAF samples from 14 women of known BRCA1 status 
who have no evidence of breast cancer: 9 mutation carriers and 5 non-carriers. LOH 
studies for BRCA1 were possible in 19/26 DL samples (Isaacs, Cavalli et al. 2004).  
This has provided evidence for the feasibility of performing molecular studies on 
DNA obtained from DL and NAF (Isaacs, Cavalli et al. 2004). 
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Individual studies of LOH has rarely spanned more than one chromosome.  
However, a pooled analysis of LOH through a complete genome scan has identified 
several tumor suppressor genes through the entire genome:  A group of researchers 
has compiled an extensive database from 151 published LOH studies of BC with 
summary data of more than 15000 tumors and had shown a striking preferential loss 
in specific regions of chromosomes 7q, 16q, 13q, 17p, 8p, 21q,3p,18q,2q and 19p as 
well as other regions (Miller, Wang et al. 2003).  
Allelic loss at BRCA1, BRCA2, and p53 seems to be a frequent event in 
sporadic BC particularly at younger age.  Several groups have reported on the 
association between sporadic cancer and loss of heterozygozity in BRCA1, BRCA2, 
and p53in sporadic cases of breast cancer (Johnson and Lo 2002; Charef-Hamza, 
Trimeche et al. 2005).  The interferon regulatory factor-1(IRF-1) gene localized on 
chromosome 5q31.1. is believed to act as a tumor suppressor gene in breast cancer 
through activities associated with caspase activation and apoptosis induction (Bouker, 
Skaar et al. 2005).  Kim, Armstrong et al (2004) has reported that the expression of 
IRF-1 induces apoptosis and inhibits tumor growth in mouse mammary cells (Kim, 
Armstrong et al. 2004).  The IRF-1 was found to be inactivated by a single nucleotide 
polymorphism (SNP) in BC.  This might indicate that the loss of its function is critical 
to the development of the disease.  Furthermore, the low IRF1 mRNA expression has 
been strongly correlated with high risk of recurrence and death (Cavalli, Riggins et al. 
2010).  
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1.7 DNA copy number changes in the genes of The phosphatidyl inositol 3-
kinase/AKT signalling pathway and its role in early breast cancer: 
Accumulating evidence indicates that the phosphatidyl inositol 3-kinase 
(PIK3)/ATK pathway (as illustrated in Figure 1. ) facilitates a number of extracellular 
signals and impacts on several cellular events like cell growth, proliferation and 
survival (Dillon, White et al. 2007).  It is believed that the (PIK3)/ATK is relatively an 
early event in breast tumorigenesis preceeding invasion.  The controlled signalling in 
cancerous cells usually happen through mutation, amplification of the Tyrosine 
Kinase or PIK3 itself (St-Germain, Gagnon et al. 2004).  The (PIK3)/AKT signalling 
is initiated by the growth factor binding  to the tyrosine kinase receptor leading to 
receptor dimerization.  As a result, lipid kinase PIK3 is recruited to the internal 
docking site and becomes activated.  PIK3 next converts membrane lipid PIP2 to its 
active PIP3 form which in turn leads to the activation of key signalling kinase, AKT. 
AKT promotes cell growth through protein synthesis driven by mTOR signalling and 
reduces cell death by blocking FOXO activity (Carracedo, Ma et al. 2008; Zhang, 
Fang et al. 2010; Logue and Morrison 2012) . 
Aberrant activation of this pathway has been implicated in many cancers as 
well as resistance to cancer therapies.  In breast cancer, aberrant expression of this 
pathway is reported in 50% of the cases and mutation in the alpha catalytic subunit of  
phosoinositol-3-kinase (PIK3CA) occurs in approximately 30% of ER Positive breast 
cancers (Ellis, Lin et al. 2010).  A group of researchers has examined the later 
mutation response to neoadjuvant endocrine therapy for ER positive breast cancer 
(Ellis, Miller et al. 2009) and found a weak negative correlation between the PIK3CA 
mutation status in those patients and their clinical response to treatment.  The study 
also documented a favourable relapse free survival rate in those patients but failed to 
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explain the mechanisms behind the improved prognostic indicators (Ellis, Miller et al. 
2009). 
The frequent dysregulation of the PIK3/AKT pathway in breast cancer has 
made the signalling players of this pathway attractive for therapeutic targeting. 
Nevertheless, a further insight and a more comprehensive evaluation  is needed to 
unravel the mysteries behind the signalling intricacies (Dillon, White et al. 2007). 
This will help to develop therapeutic agents to target not only molecules but 
functional aspects of breast cancer progression (Suter and Marcum 2007). 
 
 
Figure 1.1: The main genes involved in the PIK3 pathway (Holmes 2011)  
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Aims of the study 
The aims of this study were: 
- To detect and report on the loss of heterozygosity / allelic instability of IRF-1 
in breast cancer cases from South African women.  
- To correlate LOH of the IRF-1 gene with clinical characteristics of the patients 
(age, stage and ER status). 
- To detect and report on the genetic alteration in the PIK3 pathway in breast 
cancer cases from South African women.  
- To correlate the alterations observed in the TNBC versus non-TNBC cases. 
Therefore, this study was designed to identify genes associated with the triple 
negative tumors that serve as biomarkers for early detection, prognosis as well as 
targets for treatment.  
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CHAPTER 2 
METHODOLOGY 
2.1 Tumor and Normal Tissue Specimens 
The specimens were supplied by the National Health Laboratory Services in 
Cape Town at the Division of Anatomical Pathology (UCT).  Subsequently, ethical 
approval was obtained UCT and UWC (refer to Appendix VIII) .  A total of 101 
patients were randomly selected for this study.  A formalin fixed paraffin embedded 
block with breast tumor tissues and a second block with normal tissue were collected 
for each case from the archives of the National Health Laboratory Services in Cape 
Town at the Division of Anatomical Pathology (UCT).  The clinical data pertaining to 
age, race, tumor stage, and receptor status were obtained for each patient from the 
department of surgical pathology at Groote-Schuur Hospital.  Patients’ identities were 
kept anonymous at all stages of the project 
 
2.2 Patient characteristics 
The median age of the study population at diagnosis was 53 years (range, 22- 
80 years).  Seventy nine (79) patients were in an early tumor stage and 22 patients in 
late tumor stage.  The details on the distribution of clinicopathological factors in the 
study cohort are given in Table 2.1.  Refer to Appendix VI for the summary of 
patients’s clinical data. 
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Table 2.1: Clinicopathologic characteristics of 101 breast cancer patients 
 
 
Characteristics  Patients, no. (%) 
Age, yrs  
  ≤50 43 (42.57) 
  >50 58 (57.420 
Tumor stage  
   Early (stage I&II) 79 (78.21)  
   Late  (stage III&IV) 22 (21.78) 
Hormone receptor status  
   ER negative 45 (44.55) 
   ER positive    56 (55.44) 
   PR negative 98 (97.0) 
   PR positive  3   (2.97) 
   HER2  negative 57 (56.44) 
   HER2  positive 29 (28.71) 
   HER2  equivoeal 13 (12.87) 
   TNBC 27 (26.73) 
 
 
2.3 Histopathological examination and Micro-dissection of tissue 
In most cases, 3 consecutive 10-µm sections from each block were prepared, 
of these one was Haematoxylin & Eosin (H&E) stained.  Stained slides were initially 
examined by a pathologist for the presence of breast cancer cells.  Once found, the 
positions of these cells were marked and the consecutive slides were then micro-
dissected with a surgical needle to isolate the malignant cells to ensure pure tumor cell 
population.  Dissected tissue was then placed in 1.5ml micro centrifuge tubes.  For 
each case, a similar procedure was followed to obtain a normal tissue for the same 
patient from a different block. 
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2.4 DNA Isolation from paraffin-embedded tissue  
2.4.1 Removal of paraffin from the tissue 
For each case, the tissue was washed three times with 100l of Xylene for five 
minutes to dissolve the wax.  To concentrate DNA samples, the ethanol precipitation 
method was used, therefore the tissue was washed three times with 100l of 100% 
Ethanol for five minutes and was left to dry.  A volume of 180 µl of ATL buffer was 
added. (DNAeasy, Qiagen Inc. Valencia,Carlifonia), followed by 20µl Proteinase K. 
The micro centrifuge tubes were put  in a 55°C shaking heat block and left overnight 
until all the material was dissolved.  Proteinase K was inactivated by heating the 
samples to 95C for 10 minutes using the Thermal Cycler.  Samples were left to cool 
at room temperature.  To cleave any RNA present and ensure a pure extraction of 
DNA, free from RNA impurities 0.005 RNase A (0.6 was used) stock solution 
(20g/l) was added to achieve a final concentration of [RNase A] =0.1g/l.  The 
samples were incubated at 37C using the heat block for 1.5 hours and were left to 
cool at room temperature.  1 volume of Phenol: chloroform: isoamyl: alcohol (25: 24: 
1) was used to remove proteins from the preparation of nucleic acids and vortexed for 
15 seconds and centrifuged at 14 000 rpm for 5 minutes.  The aqueous (top) layer was 
transferred to a new tube. One (1) volume of Phenol : chloroform : isoamyl alcohol 
(25: 24:1) was added again,  vortexed for 15 seconds and centrifuged at 14 000 rpm 
for 5 minutes.  The aqueous (top) layer was transfered to a new tube.  A 0.2 volume of 
10M Ammonium acetate (NH4OAc) to achieve final [NH4OAc]=2M was added.  A 
0.08 volume of glycogen (8l used) was added and 2 x volumes of 100% Ethanol was 
added (200l used).  The samples were left at -20C freezer overnight.  The next day 
the samples were centrifuged at 14 000 rpm for 20 minutes. The supernatant was 
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removed while being careful to retain the DNA pellet.  The pellet was rinsed with 1ml 
70% ethanol and the samples were centrifuged at 14 000 rpm for 5 minutes.  Ethanol 
was removed and the pellet was left to dry.  The pellet was re-suspended in 50l of 
T.E (30l of DNA Hydration solution was used) and the tubes were incubated at 65C 
using the shaking heating block for two hours.  
 
2.5 Quantification of DNA 
The purity and yield of the total DNA was measured spectrophotometrically at 
260 and 280 nm using a NanoDrop 1000 (Thermo scientific, USA).  The presence of 
DNA was checked by gel electrophoresis (Appendix Ia and Ib). 
 
2.6 Polymerase chain reaction (PCR) 
 Aliquots of DNA (2µg) were transferred to 25µl reactions containing final 
concentrations of 1X PCR buffer, 1.5 mM MgCl2, 10 µM of each upstream and 
downstream primer, 0.1 mM of each dNTP, 1.5 U of GoTaq
 
DNA polymerase and 
nuclease free water.  All reagents were from Whitehead Scientific (Cape Town, South 
Africa) except when otherwise indicated.  
PCR samples were amplified on a Multi Gene II gradient thermal cycler 
(Labnet, UK) as follows:  The first PCR cycle consisted of denaturation at 94°C for 5 
minutes.  This was followed by 35 cycles at 94
°
C for 30 seconds, 55°C for 30 seconds 
(the annealing temperature for the IRF-1 gene) and 72
°
C for 30 seconds, then a final 
extension at 72º C for 10 minutes.  Optimization of the annealing temperature was 
carried for the IRF1 gene to select the optimal annealing temperature for this gene. 
 
 
 
 
26 
 
 PCR products were separated by electrophoresis on a 2% agarose mini-gel  
(containing 0.5 µg/ml ethidium bromide).  Thereafter, the bands of interest were 
analyzed with the Doc-ItLS® Image Acquisition Software, Version 5.5.5a (Doc-It 
Life Sciences Software,UVP™, Inc., San Gabriel, USA) and viewed under a UV 
Transluminator (UVP™, Inc.,San Gabriel, CA 91778, USA).  A positive result was 
recorded when a band of the appropriate size (187bp) as ascertained by comparison 
with a 100-bp ladder was visible on the gel. (refer to Appendix III).  Opening of the 
tubes containing PCR products and gel electrophoresis were always performed under 
negative atmospheric pressure to prevent subsequent amplicon contamination of DNA 
samples or RT-PCR reagents.  The sequences of the oligonucleotide primers were 
obtained from the Genome Data Base (GDB) (http://www.gdb.org):  Forward: 5′-
ATGGCAGATAGGTCCACCGG-3′/ Reverse: 5′-TCATCCTCATCTGTTGTACG-3′ 
(Appendix II).  Primers were fluorescently labeled.  Synthesis and purification of each 
primer set was done by Whitehead Scientific (South Africa).  
Table 2.2: Primer pairs amplicons lengths, sequences and melting temperature of 
the IRF1 gene: Evaluated by conventional RT-PCR. Primer position on the sequence 
(Appendix II). 
 
Gene 
 
Product 
size 
 
Gene 
Bank 
Accession 
Number 
 
Primers Sequence 
 
Tm 
IRF1 187bp NC_00000
5 
Forward: 5′-ATGGCAGATAGGTCCACCGG-3′/ 
 
Reverse: 5′-TCATCCTCATCTGTTGTACG-3′. 
F 55 ºC 
R 55 ºC 
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2.7 Loss of Heterozygosity (LOH) analysis 
To study LOH at the IRF-1 locus, we selected an intragenic, dinucleotide, 
polymorphic marker (IRF1 Dinucleotide Repeat, Allele Set GDB: 211036), with a 
high degree of heterozygosity (74% heterozygosity).  The sequences of the 
oligonucleotide primers were obtained from the Genome Data Base (GDB) 
(http://www.gdb.org): Forward: 5′-ATGGCAGATAGGTCCACCGG-3′/Reverse: 5′-
TCATCCTCATCTGTTGTACG-3′.  Primers were fluorescently labeled and PCR 
amplification was performed using a standard protocol.  Allele sizes were determined 
by electrophoresis of PCR products in 6% denaturing polyacrylamide gels and were 
compared to ROX 500 size standards (Applied Biosystems, Foster City, CA), using an 
automated sequencer (ABI 377), according to the manufacturer’s instructions 
(Applied Biosystems).  Fluorescent signals from the different size alleles were 
recorded and analyzed using GENOTYPER version 2.1 (Appendix IV) and 
GENESCAN version 3.1 software (Applied Biosystems).  Following visual 
examination of computer printouts by two independent observers, LOH was 
determined mathematically according to the Genotyper User’s Manual (Applied 
Biosystems). 
 
2.8 DNA copy number assay:  
TaqMan copy number assays (Applied Biosystems, CA), to identify gene copy 
number changes in the PIK3 genes (ATK1, ATK2, PIK3CA, PTEN, FGFR2) were 
performed in the microdissected DNA isolated from the FFPE tumor sections and 
from the normal control (pool of DNA from multiple female donors with no cancer).  
The samples were diluted to 5ng/μl and amplified in the ABI 7500 HT Real Time 
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PCR instrument (Applied Biosystems, Foster City, CA, USA) using PIK3 specific 
probes and primers.  The RNASE P gene was used as a reference.  The gene sequences 
were based on the hg19.v9 genomic database.  The probe locations of the PIK3 and 
RNASE P genes were as follows: ATK1 105241518, ATK2 40761052,  PIK3CA 
178876317, PTEN 89685514, FGFR2 123325143 and 157907524 (14q11.2), 
respectively.  PIK3 and HER2/NEU probes were labeled with the fluorescent dye 
FAM and RNASE P with VIC dye (detailed information of the probes used and PCR 
conditions are shown in Table 2.3).  PCR was performed in a total volume of 10μl in 
each well of a 96-well plate, which contained TaqMan Universal MasterMix (Applied 
Biosystems), 5ng of genomic DNA and 12.5 picomoles per liter concentration of each 
primer and probe.  PCR conditions included an initial denaturation step of 95°C for 10 
minutes, followed by 40 cycles at 95°C for 15 seconds and 60°C for 1 minute.  All of 
the reactions were carried out in triplicates, and a negative control with no DNA 
template was included in every PCR run.  For all PCR assays, crossing threshold (Ct ) 
numbers were established using SDS 2.2 RQ software (Applied Biosystems), and the 
copy numbers were normalized against the reference gene (RNASE P) and determined 
by the 2
-ΔΔCt
 method.  Copy number changes were only considered for samples that 
presented CT cycles < 33 and a Z-score value < 2.65.  A two-fold increase or decrease 
in the copy number of PIK3 genes in tumor samples in comparison to the normal 
control was considered as amplification or deletion, respectively.  
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Table 2.3: Probes and PCR cycle used for the TaqMan Copy number assay. 
 TaqMan Probes 
Position Labeling 
Target Genes ATK1 105241518 5’=Reporter-FAM 
3’=Quentcher- nao fluorescent ATK2 40761052 
PIK3CA 178876317 
PTEN 89685514 
FGFR2 123325143 
Reference gene RNASE P      157907524 5’=Reporter-VIC 
3’=Quencher-TAMRA 
Master Mix Taq Gold DNA polymerase (Hot start), dNTPs 
PCR cycle Hold: 95ºC-10 minutes 
40 cycles: 
95ºC- 15 seconds/60ºC- 60 seconds 
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CHAPTER 3 
 
RESULTS 
 
3.1 Loss of heterozygosity (LOH) analysis for IRF-1 
LOH is the loss of one allele at a specific locus, caused by a deletion,  
mutation; or loss of a chromosome from a chromosome pair, resulting in abnormal 
hemizygosity.  This is detected when heterozygous markers for a locus appear 
monomorphic due to the deletion of one of the alleles.  When this occurs at a tumor 
suppressor gene locus where one of the alleles is already abnormal, it can result in 
neoplastic transformation (Fujii, Ajioka et al. 2002).  
In this study, 46 cases (45.5%) out of 101 cases were informative for the IRF-1 
dinucleotide marker used for LOH analysis.  Figure 3.1. shows that LOH was detected 
in 23 of these informative cases (23/46; 50%).  There was no statistical significance 
between LOH at the IRF-1 locus and both older age (P value = 1.0000) and earlier 
stage (Stages I and II) (P value= 0.4982) based on Fisher’s exact test. 
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Figure 3.1: Pie chart representing cases of LOH at the IRF-1 gene on 101 
samples. 23 cases with loss of heterozygosity (LOH), 23  cases with no loss of 
heterozygosity (No LOH), 15 cases that were non-informative (NI) and 40 cases that 
were non dictatable (ND). 
Figure 3.2 dipicts the PCR results for the amplification of the IRF-1 gene of 
cases 1 to 11 on tumor tissue samples and the remainder of the samples are shown in 
Appendix III. 
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Figure 3.2: PCR amplification of the IRF-1 gene of Cases 1-11 on tumor tissue.  
Lane 1: 100 bp DNA Marker; Lane 2: Negative control; Lane 3: Positive control; 
Lane 4: sample 1; Lane 5: sample 2; Lane 6: sample 3; Lane 7: sample 4; Lane 8: 
sample 5; Lane 9: sample 6; Lane 10: sample 7; Lane 11: sample 8; Lane 12: sample 
9; Lane 13: sample 10; Lane 14: sample11.  The arrow indicates expression of IRF1 at 
187 bp. 
Figure 3.3 depicts the detection of loss or no loss of heterozygosity, and the 
remainder of the samples are shown in appendix IV a, b & c.  The y axis represents 
allele frequency and the x axis represent the allele base-pair length.  In Figure 3.3, A 
represents a case with LOH and B represents a case with no LOH.  On the figure a 
and b Top panels represent the analysis performed in normal cells and the bottom 
panels represent the analysis performed in tumor cells.  
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Figure 3.3: LOH analysis at the IRF-1 locus of two representative breast cancer cases. 
A on the figure represents a case with LOH.  B represents a case with no LOH.  In a, 
b, Top panels shows the analysis performed in normal cells and bottom panels the 
analysis performed in tumor cells.  The y axis represent allele frequency and the x 
axis represent the allele base-pair length 
3.2  Correlation between loss and no loss of heterozygozity with other parameters 
3.2.1  Correlation between loss and no loss of heterozygozity with age. 
The striking correlation between advanced age and an increased incidence of 
cancer has led investigators to examine the influence of aging on genome 
maintenance.  Since the loss of heterozygosity (LOH) can lead to the inactivation of 
tumor suppressor genes, and thus carcinogenesis, understanding the effect of aging on 
this type of mutation event is particularly important.  There are several factors that 
may affect the rate of LOH, these include (i) an increase in the amount of DNA 
damage; (ii) specifically double-strand breaks (DSBs), and (iii) the ability to 
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efficiently repair this damage via pathways that minimize the loss of genetic 
information.  Because of experimental constraints, there is only suggestive evidence 
for a change in the rate of DNA damage as humans age (August, Rea et al. 1994). 
However, recent studies in model organisms find that there are increased rates 
of LOH with age, and that repair of DNA damage occurs via a different pathway in 
old cells versus young cells.  It is speculated that the age-dependent change in DNA 
repair may explain why there is increased LOH, and that the findings from these 
model organisms may extend to humans (Carr and Gottschling 2008).  
Table 3.1 depicts that there is no statistical significance (P=1.0000) between age (≤50 
years or >50 years), LOH and no LOH.  The results in the table show cases with LOH 
and are ≤50 years (23.9%), cases with no LOH and ≤50 years (26.08%), cases with 
LOH and >50years (26.08%) and cases with no LOH >50 years (23.91%). 
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Table 3.1 The correlation of  LOH, NO LOH with ages ≤ 50 and > 50 years.  
 
 
3.2.2 Correlation between loss and no loss of heterozygozity with tumor stage 
The development of human cancer is generally thought to entail a series of 
events that cause a progressively more malignant phenotype.  This hypothesis predicts 
that tumor cells of the ultimate stage will carry each of the events, cells of the 
penultimate stage will carry each of the events less the last one and so on.  That is to 
say, a dissection of the pathway form a normal cell to a fully malignant tumor may be 
viewed as the unraveling of a nested set of aberrations (Cavenee 1989). 
Most LOH studies of breast cancer provide limited or no specification of 
tumor stage or histology, presenting an additional challenge in comparing across 
studies.  For all of these reasons, previous summaries of LOH in breast cancer have 
been largely qualitative, consisting of descriptions of chromosomal arms or regions 
reported frequently lost (Lasko, Cavenee et al. 1991).  Wang et.al (2003) evaluated 
the potential utility of occult circulating tumor DNA as a molecular marker of disease 
  Age  
    ≤50 years     >50 years TOTAL 
LOH 11 (23.91%) 12 (26.08%) 23 
NO LOH 12 (26.08%) 11 (23.91%) 23 
TOTAL 23 (49.99%) 23 (49.99%) 46 
 
P value =1.0000 
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in subjects previously diagnosed with breast cancer, and found no association, 
between plasma LOH and tumor stage or clinical status at time of blood collection 
(Wang, Larson et al. 2003). 
In this study the results in Table 3.2 indicate that there is no statistical 
significance (P value = 0.4982) between loss and no loss of heterozygozity with tumor 
stage.  This was observed from 44 samples which indicated that 16 (15.8%) cases had 
LOH,16 (15.8%) had no LOH and both groups were at early stages (I and II).  Eight 
samples (7.9%) had LOH, four (4%) had no LOH and both groups were at a late 
breast cancer stage (III and IV). 
Table 3.2: The correlation of  LOH, NO LOH with early and late stages.  
 
 Stage  
  Early stage Late stage TOTAL 
LOH 16 (15.8%) 8 (7.9%) 24 
NO LOH 16 (15.8%) 4 (4%) 20 
TOTAL 32 (31.6%) 12 (12%) 44 
 
P value = 0.4982 
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3.2.3 Correlation between loss of and no loss of heterozygozity with Estrogen  
receptor gene 
Table 3.3 indicates that there is a statistical significance (P=0.0009) between 
loss and no loss of heterozygozity with ER gene.  This was observed from 37 samples 
which indicated that 15 (14.9%) cases had LOH, 11 (10.9%) had no LOH and both 
groups were ER+,  No (0) samples had LOH and 11 (10.9%) had no LOH and were 
ER-. 
Table 3.3:  The correlation of LOH, NO LOH with Estrogen receptor gene (+ve/-
ve). 
 Estrogen receptor  
        ER +ve ER -ve TOTAL 
LOH 15 (14.9%) 0 (0%)    15 
NO LOH 11 (10.9%) 11 (10.9%)    22 
TOTAL 16 (26%) 11 (11%)    37 
 
P=0.0009 
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3.4 DNA copy number changes on specific genes in the PIK3 pathway 
3.4.1 DNA copy number changes in genes involved in the PIK3/AKT signalling 
pathway.  
In this study patients presented a high level of DNA copy number changes in 
genes involved in the PIK3/AKT pathway as depicted in Table 3.4  The most frequent 
changes were observed in the PIK3CA and PTEN genes.  PIK3CA presented high 
copy number in 36.8% of the cases.  PTEN was observed with low copy number in 
47.5% of the cases. 
Table 3.4 : DNA copy number assay for AKT1, AKT2 and PTEN genes in the non- 
TNBC. 
Gene Normal copy 
number  
n (%) 
High copy 
number 
n (%) 
Low copy  
number  
n (%) 
ATK1 22 (57.9%) 7   (18.4%) 9   (23.7%) 
ATK2 25 (65.8%) 9   (23.7%) 4   (10.5%) 
PIK3CA 14 (36.8%) 14 (36.8%) 10 (26.3%) 
PTEN 15 (39.5%) 5   (13.1%) 18 (47.4%) 
FGFR 20 (52.6%) 7   (18.4%) 11 (28.9%) 
 
 
3.4.2 DNA copy number assay for AKT1, AKT2 and PTEN genes for patients with 
breast tumor (TNBC and non-TNBC) from the South African population  
Patients with breast tumor (TNBC and non-TNBC) from the South African 
population present a high level of DNA copy number changes in genes involved in the 
PIK3/AKT pathway as indicated in Figure 3.4 and Figure 3.5. 
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Figure 3.4: Represents DNA copy number assay for AKT1, AKT2 and PTEN genes in 
non- TNBC from South African patients. *indicates a normal control. The y axis 
represents the DNA copy number  and the x axis represents the number of a non 
TNBC sample from the 101 samples:  
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(a) For the AKT1 gene samples 1, 101, 20, 29, 35, 37, 41,42, 48, 49, 50, 53,  
55, 56, 57, 61, 62, 63, 64. 65, 67, 71, 72, 73, 74, 75, 77, 78 79, 8, 81, 82, 
83, 84, 86, 89, 91, 94, 97, 99, NC. 
(b) For the AKT2 gene samples: 1, 101, 15, 73, 43, 49, 50, 53, 55, 56, 57, 61,  
62, 63, 64, 65, 67, 71, 73, 74, 75, 77, 78, 79, 8, 80, 81, 82, 83,  86, 89, 91, 
94, 97, NC  
(c) For the PTEN gene samples: 1, 101, 29, 35, 37, 48, 49, 50, 53, 56, 57, 61,  
62, 63, 64, 64, 67, 71, 72, 73, 74, 75, 77, 78, 79, 8, 80, 81, 82, 83, 86, 89, 
91, 94, 97, 98, 99, NC. 
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Figure 3.5: DNA copy number assay for (a) AKT1, (b) AKT2 and (c) PTEN in the 
TNBC from South African patients. (*) indicates normal control (NC) . The  y axis 
represents the DNA copy number  and the x axis represents the number of TNBC 
samples from the 101 samples:  
(a) For the AKT1 gene samples: 14, 32, 44, 55, 71, 85, 90, 98 and NC 
(b)  For the AKT2 gene samples: 14, 32, 44, 85, 90, 98, NC 
(c) For the PTEN gene samples: 14, 32, 44, 85, 90, 98, NC 
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CHAPTER 4 
DISCUSSION 
The emerging fact that BC has a heterogenous biological behaviour has 
warranted extensive research.  For the past two decades, researchers have tried to 
stratify BC in order to find improved means for early diagnosis and ultimately better 
therapeutic approach.  As a result of genomic instability, cancer cells have been found 
to accumulate both random and causal alterations at multiple levels, ranging from 
point mutations to whole chromosome aberrations (Huang, Wei et al. 2004).  
Examples of DNA copy number changes include, but are not limited to, loss of 
heterozygosity (LOH) and homozygous deletions, which may result in the loss of 
tumor suppressor genes, and gene ampliﬁcation events, which can activate cellular 
proto-oncogenes (Huang, Wei et al. 2004). 
Like other solid cancers, breast cancer presents genomic instability (Li, Wang 
et al. 2009).  The existing concept is that frequently occurring regions of DNA 
amplification commonly harbor oncogenes, whereas regions of recurrent deletion are 
known to harbor tumor suppressor genes (Li, Wang et al. 2009).  Classical 
cytogenetic methods have been used to detect such copy number changes in tumors, 
which have deepened our understanding of the genomic hallmarks of breast cancer 
(Li, Wang et al. 2009).  The main objective of this study was to find markers for the 
detection of genomic instability in South African women.  The further aim was to be 
able to correlate these genomic changes with the age, receptor status and staging, to 
gain an insight into the prognostic significance of these markers. 
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The specimen chosen for this study were primary tumors obtained from the 
archives of National Laboratory Health Sciences (NLHS) after obtaining ethics 
approval.  Formalin-fixed, paraffin-embedded (FFPE) tissues are one of the popular 
sources of diagnostic materials, the easiest to store and transport.  They are often used 
as the source of nucleic acids for retrospective molecular analyses based on DNA 
amplification by polymerase chain reaction (PCR).  A study has shown that the LOH 
is better detected in tumor tissues than haematological specimens like blood and bone 
marrow (Schwarzenbach, Muller et al. 2007).  However, it is known that nucleic acids 
from paraffin embedded tissues are much worse templates than those recovered from 
fresh tissues (Bielawski, Zaczek et al. 2001) and is mainly due to the low yield of 
genetic material and the difficulty in getting intact DNA. 
The low yield of DNA from our archival samples was one of the major 
obstacles in this study.  This has been reported in other studies (Al-Mulla 2011).  One 
of the future approaches  to achieve high throughput for LOH mapping is through the 
use of Capillary array electrophoresis and laser-assisted microdissection (Ellsworth, 
Shriver et al. 2003).  Mutiple sections were explored in order to ensure the generation 
of intact DNA material. 
The choice of control was problematic as we initially intended to use blood 
samples as controls, however, the ethics approval committee has objected to that and 
we were only left with the use of normal breast tissue as a control.  A study evaluated 
LOH in normal breast epithelial tissues and benign breast lesions around the tumor 
and found them to harbour LOH (Cavalli, Singh et al. 2004).  To overcome this, we 
have asked the pathologist  to provide samples of normal breast tissue away from the 
perimeter of the tumor but blood samples remains as more suitable control. 
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Clinically advanced tumor stage and tumor grade are recognized prognostic 
factors in breast carcinoma (Henson, Ries et al. 1991; Page 1997).  Gupta et.al (2009) 
found that all the tumors having LOH, were of high grade (grade II and III). These 
findings suggest that the accumulation of allelic losses  might play an important role 
in tumor progression(Gupta, Joshi et al. 2009).  In contrast, there is no significant 
difference in LOH frequency with respect to age, tumor stage, menopausal status, 
chemotherapy or lymph node metastasis (Hirano, Emi et al. 2001). 
In this study, the association between LOH and stage is not statistically 
significant.  There was no significance difference in early stage (15.8%) as compared 
to late stage (7.9%) in determining the LOH effect.  
To detect genomic instability, two approaches were used; the first was to 
attempt to detect allelic instability or LOH at the IRF-1 region of chromosome 5. 
The loss of heterozygosity indicates that at one of the constitutional loci, a normally 
functioning allele was lost (Skotheim. 2001; Miller, Wang et al. 2003).  This loss is 
commonly found in different types of cancers, including breast cancer, cervical cancer 
and squamous cell carcinoma (Huettner, Gerhard et al. 1998; Miller, Wang et al. 
2003).  In most types of cancer this loss can be mapped, should it occur in a non-
random fashion, and thereby implicating specific tumor suppressor genes in the 
progression of a cancerous state (Skotheim. 2001).  Total knockout of a tumor 
suppressor gene can occur, whereby one allele has been mutated or imprinted, and this 
is enhanced by the loss of heterozygosity (Skotheim. 2001).  To detect for differences 
in two alleles at a locus, the intensity ration can be measured (Skotheim. 2001; Miller, 
Wang et al. 2003).  A skewed intensity ratio is known as allelic imbalance and this 
indicates the possible loss of an allele due to masking, heterogeneity or non-clonal 
loss (Skotheim. 2001; Miller, Wang et al. 2003). 
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The choice of the IRF1 gene has been based on reports of loss of 
heterozygosity and deletions associated with chrosome 5 in TNBC and BRCA1 cases  
(Wang, Lin et al. 2004; Bergamaschi, Kim et al. 2006).  In addition,  other researchers 
have reported on its characteristics as a promising candidate marker for the detection 
of loss of heterozygosity in primary breast tumors (Cavalli, Riggins et al. 2010).  It 
was also documented that IRF1 has a remarkable functional diversity and controls the 
transcription of genes involved in mediating antiviral, immunomodulatory, and 
antiproliferative effects (Tamura, Tailor et al. 2005).  It was postulated that IRF-1 can 
act as a potential tumor suppressor gene through the regulation of oncogenesis and 
elimination of precancerous cells through apoptosis induced by DNA damage or other 
stimuli (Tamura, Ishihara et al. 1995).  
In this study allelic loss of IRF-1 was detected in 23/46 (50%) breast tissue 
specimens.  This is slightly lower than what is reported by another study on American 
women where 52 women were investigated for LOH at IRF-1 locus. 37 cases were 
informative  and had presented a 32% (12 /37) LOH at IRF-1 (Cavalli 2009).  
Although studies of mammalian cells consistently reveal an increased 
frequency of mutations with advanced age, the experimental data to date do not 
clearly demonstrate any age-dependent change in the rate of LOH in vivo.  Several 
studies demonstrate an overall functional decline in different types of DNA repair 
with age.  Perhaps the most interesting finding in the studies of age-induced LOH, is 
the evidence for a change in the mechanism of repair (Carr and Gottschling 2008).  
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In this study, there was no statistical significance (P=1.0000) between age 
(≤50 years or >50 years) with the presence or absence of LOH.  In summary, our 
understanding of the association between age-induced LOH remains incomplete. 
DNA copy number variations (CNVs) are seen to be an important component 
of genetic deviation, which is known to affect a greater fraction of the genome than 
single nucleotide polymorphisms (Shlien and Malkin 2009).  The characterization of 
widespread CNVs has provided insight into their role in susceptibility to an extensive 
range of diseases, and has been found that somatic CNVs can be used to identify 
regions of the genome involved in disease phenotypes (Shlien and Malkin 2009). 
Ultimately, changes in DNA copy number can be associated with many human 
cancers (Huang, Madireddi et al. 2001; Huang, Wei et al. 2004; Wang, Lin et al. 
2004).  A very interesting recent study compared CNVs between FFPE samples from 
104 African (Malian) women who had undergone mastectomy and another cohort of 
patients from USA and found significant differences in genomic profiling (GNVs) in 
six chromosomal regions (Madanikia, Bergner et al. 2012).  
In this study, our second approach was to determine the DNA copy number 
changes of specific genes involved in the PIK3/AKT signaling pathway in our 
samples.  Genes associated with PIK3 pathway are known to be expressed in 50% of 
BC (Samuels and Ericson 2006).  PI3K signaling is activated in human cancers via 
several different mechanisms (Samuels and Velculescu 2004).  Increased PI3K 
signaling is often due to direct mutational activation or amplification of genes 
encoding key components of the PI3K pathway such as PIK3CA and AKT1, or loss of 
PTEN (Bader, Kang et al. 2005; Samuels and Ericson 2006). 
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The most common genetic alteration of the PI3K signalling pathway found in 
human cancer is inactivation of the PTEN tumor suppressor gene.  Inactivation of 
PTEN leads to loss of its lipid phosphatase activity, causing accumulation of PIP3 
(Haas-Kogan, Shalev et al. 1998; Myers, Pass et al. 1998). 
In this study patients with breast tumor (TNBC and non-TNBC population) 
presented a high level of DNA copy number changes in genes involved in the 
PIK3/AKT pathway.  The most frequent changes were observed in the PIK3CA and 
PTEN genes. PIK3CA presented high copy number in 36.8% of the cases. PTEN was 
observed with low copy number in 47.5% of the cases. 
For ATK1 gene, 22 (57.9%) cases had normal copy number, 7 (18.4%) cases 
presented a high copy number and 9 (23.7%) cases presented a low copy number.  For 
the ATK2 gene 25 (65.8%) cases presented a normal copy number, 9 (23.7%) cases 
presented a high copy number and 4 (10.5%) cases presented a low copy number.  For 
the PIK3CA gene 14 (36.8%) cases presented a normal copy number, 14 (36.8%) 
cases presented a high copy number and 10 (26.3) cases presented a low copy 
number.  For the PTEN gene 15 (39.5%) presented a normal copy number and 5 
(13.1%) high copy number and 18 (47.4%) a low copy number. For FGFR gene 20 
(52.6%) presented a normal copy number, 7 (18.45%) a high copy number and 11 
(28.9%) a low copy number.  Furthermore, there was a significant difference in our 
indicators when compared with a Brazilian cohort (Unpublished data). 
The Copy Caller Software (Applied Biosystems, CA) results revealed 
alterations in the DNA copy number in the samples analyzed.  These changes were 
very significant and was at a higher level than the control group (please refer to the 
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results section) indicating the suitability of these genes for breast cancer detection in 
South African patients. 
The further aim of this study was to correlate our genomic findings with the 
clinical follow-up data obtained for our candidate genes in order to establish whether 
these genes have prognostic significance.  One of the concepts explored was the 
concept of TNBC, defined by a lack of expression of both estrogen (ER) and 
progesterone (PgR) receptors as well as human epidermal growth factor receptor 2 
(HER2) (Ovcaricek, Frkovic et al. 2011).  Since this phenotype is common among 
women of African descent and know to have poor prognosis, we were keen to find out 
the percentage of TNBC in our cases.  In this study, 27 cases (26.73%) out of 101 
were triple negative (TBNC).  The ER/PR pharmDx™ Scoring system interpretation 
manual (Allred scoring guidelines) was used to analyse the data.  However, a bigger 
sample size that is not ethnically diverse might give a better reflection of the actual 
predominance of TNBC in SA populations. 
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CONCLUSION AND FUTURE OUTLOOK 
Genetic instability is an early indication of malignant changes.  Two 
approaches were adopted in this study to detect genomic instability: Loss of 
heterozygosity and DNA copy number variations.  
Our data analysis indicated that 46 cases (45.5%) out of 101 cases were 
informative for the IRF-1 dinucleotide marker used for LOH analysis.  LOH was 
detected in 23 of these informative cases (23/46; 50%) which shows that IRF-1 is a 
good marker for early BC detection in primary tumors.  Furthermore, of the genes 
involved in the PIK3 pathway, the most frequent changes were observed in the 
PIK3CA and PTEN genes.  PIK3CA presented high copy number in 36.8% of the 
cases. PTEN was observed with low copy number in 47.5% of the cases when 
compared with the control indicating their validity as BC markers. 
We believe that future research should focus on other means of detecting 
genomic instability.  The actual percentages of TNBC patients still need to be 
verified.  
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Appendices 
Appendix I (a) 
DNA quantification table: DNA yield for each sample was quantified using a Thermo 
Scientific Nanodrop 1000 Spectrophotometer. 
Samples 1-101 DNA concentration for tumor tissue 
Sample ng/µl 260/280 
1 343.1 2.05 
2 527.9 2.25 
3 2245.2 2.02 
4 1954.0 1.94 
5 1442.5 1.86 
6 1194.1 1.82 
7 1462.9 1.84 
8 1237.5 1.72 
9 1198.2 1.78 
10 1428.9 1.82 
11 1461.4 1.82 
12 1436.7 1.84 
13 1246.0 1.80 
14 1284.6 1.81 
15 1137.4 1.78 
16 1813.6 1.86 
17 1534.8 1.82 
18 1646.4 1.84 
19 1828.1 1.84 
20 1367.1 1.79 
21 419.5 2.01 
22 400.2 1.97 
23 432.8 2.03 
24 445.2 2.09 
25 405.6 2.01 
26 557.2 2.15 
27 484.7 2.04 
28 341.9 1.94 
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28 772.6 1.81 
30 411.6 2.07 
31 705.4 1.76 
32 464.6 2.04 
33 337.6 1.94 
34 437.7 2.00 
35 496.3 1.99 
36 445.5 2.07 
37 521.9 2.04 
38 425.3 2.03 
39 342.7 1.93 
40 437.2 1.96 
41 54.8 1.91 
42 31.7 1.68 
43 53.9 1.79 
44 64.3 1.73 
45 117.0 1.85 
46 95.3 1.77 
47 108.6 1.81 
48 101.1 1.75 
49 109.4 1.78 
50 47.1 1.64 
51 27.2 1.57 
52 60.7 1.79 
53 17.8 1.50 
54 37.6 1.72 
55 105.6 1.79 
56 20.5 1.46 
57 74.5 1.72 
58 105.6 1.79 
59 86.0 1.77 
60 18.1 1.44 
61 111.4 1.76 
62 136.5 1.76 
63 131.8 1.78 
64 118.6 1.66 
65 168.4 1.82 
66 70.3 1.72 
67 101.9 1.77 
 
 
 
 
66 
 
68 137.4 1.76 
69 159.4 1.82 
70 163.9 1.81 
71 48.8 1.74 
72 93.0 1.73 
73 115.3 1.78 
74 158.9 1.79 
75 110.7 1.76 
76 90.4 1.75 
77 108.5 1.72 
78 128.2 1.74 
79 131.7 1.77 
80 157.8 1.76 
81 40.7 1.65 
82 140.8 1.69 
83 345.7 1.72 
84 360.2 1.79 
85 314.2 1.75 
86 217.9 1.70 
87 228.0 1.69 
88 884.1 1.54 
89 219.2 1.63 
90 188.2 1.65 
91 215.7 1.68 
92 202.7 1.65 
93 332.1 1.79 
94 121.0 1.66 
95 102.5 1.65 
96 567.8 2.07 
97 332.3 1.75 
98 418.5 1.84 
99 333.3 1.75 
100 344.6 1.75 
101 247.4 1.68 
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Appendix I (b) 
DNA quantification table: DNA yield for each sample was quantified using a Thermo 
Scientific Nanodrop 1000 Spectrophotometer. 
Samples 1-101 DNA concentration for normal tissue 
Sample number                                ng/µl 260/280 
1 16.8 1.36 
2 38.2 1.37 
3 26.6 1.51 
4 43.4 1.57 
5 43.4 1.5 
6 28.2 1.39 
7 59.5 1.58 
8 58.3 1.57 
9 40.1 1.47 
10 22.9 1.32 
11 3.7 0.84 
12 16 1.29 
13 76.8 1.68 
14 200 1.21 
15 42.1 1.59 
16 38.4 1.53 
17 38.4 1.53 
18 3.6 0.71 
19 49.1 1.54 
20 24.1 1.5 
21 1.2 1.08 
22 56.5 1.63 
23 43.4 1.63 
24 54.7 1.62 
25 4.9 1.5 
26 33.2 1.54 
27 56.2 1.5 
28 24.3 1.62 
29 22.6 1.66 
30 20.3 1.63 
31 18.4 1.52 
32 23.7 1.36 
33 8.1 1.57 
34 26 1.52 
35 27.8 1.5 
36 8.6 1.22 
37 7 1.71 
38 39.1 1.68 
39 10.5 1.82 
40 10.9 1.66 
41 6.2 1.72 
42 13.2 1.51 
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43 38.2 1.47 
44 13.1 1.61 
45 25.2 1.65 
46 7.3 1.42 
47 36.3 1.57 
48 42.2 1.62 
49 10.7 1.5 
50 7.3 1.88 
51 47.7 1.59 
52 28.6 1.67 
53 45.4 1.57 
54 38.5 1.63 
55 35.7 1.54 
56 10.8 1.5 
57 15.6 1.49 
58 30.2 1.64 
59 11.8 1.44 
60 120.5 1.69 
61 20.8 1.74 
62 31.9 1.56 
63 59.5 1.58 
64 21 1.57 
65 31.4 1.54 
66 49.8 1.65 
67 17.8 1.51 
68 25.9 1.51 
69 20.8 1.56 
70 15.3 1.96 
71 120.5 1.69 
72 63 1.76 
73 32.4 1.62 
74 15.7 1.98 
75 15.4 1.95 
76 10.6 1.61 
77 19.6 1.57 
78 23.2 1.58 
79 21.7 1.51 
80 29.8 1.65 
81 73.5 1.71 
82 52 1.63 
83 56.6 1.74 
84 40.4 1.5 
85 18.5 1.43 
86 29.7 1.62 
87 32.1 1.49 
88 36.3 1.53 
89 30.3 1.59 
90 49.1 1.65 
91 13.6 1.31 
92 23.9 1.57 
93 35.1 1.61 
94 43.1 1.64 
95 16.8 1.53 
96 56.4 1.58 
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97 6.9 1.53 
98 10.8 1.4 
99 51.5 1.58 
100 35.7 1.54 
101 34.8 1.52 
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Appendix II 
IRF-1 Primers position on the transcripts. Different exons are sequentially marked in 
alternating blue and pink. 
  Gene: IRF-1 
   Accession number: NC_000005 
   Transcript length: 11915 bp 
Forward Primer 
 
Reverse Primer 
 
   ORIGIN       
      1 TGGAGGGAGA GCTGGGGTGA AGGAAATGAC ACGCCTGGGA GAGTAACTTA CTTCTGCAGG 
       61 AGCTTTAGGG AGATGAAGGA AGAAGCCTCC TGGGCCAGAG TTTTGGATGG AAAATGAACA 
      121 CCCAGTCAAG TCTCTAGGAC TATACGTGGG GCGGGGACTA GTTGTGCGCG AGAGTTAAGT 
      181 AGGGGCCTTA CCAAGGAGCA TGGGACCTGG GCTCCCCAAC CCTTTGGCTA GCCCCATGGC 
      241 GTTGATCAGC CCTGAGCTAA TTCCTCCATG CTGCCCAGAA CCTCTCTGGG CCAAGCCCTG 
      301 GGGACTCAGA GATGACAGCA ATGCTTCCAT TGCGGAACTC CCATACGCGG GCCACAGGGA 
      361 GGCTCTGGAG GCGGCCTGAG GCAAGAGTGC TAGGAGGGAT CAGAGCTAGC CCACCCCTAC 
      421 CCTCACTCAG CCGTCTGGGC TTCTCTGAAC CCCTTCTCCT CCTCTGTTCC CTAAAGCCAG 
      481 CCAGGGGGAG TCCCAGGGAG GCAGACCGAA AAGGGGTGGG GTGTCATCCT GGTCACTATT 
      541 AGACCCTGCA ACGGCGACCT TGAAAACTAC TCAGCGTCTG TTGCCCGAGT GGAGCATAGT 
      601 GCTTTACAAT CTCTTCCCAT CACAGCAAAC CATCAAGGTA GGGCTACTAT TATTTTATGG 
      661 TTGAAAAACA GAGGTCCTGC GTCCCTTGGG GGCTGTGCCA GCAGCGGCCA AGTTGGGATT 
      721 TCCCCTGGTC CAGCAGCCCC AGACAGCACA CGGGGCAGGG TAGGCTTTCT GCCTTCTTCA 
      781 CTTCCCCAGG GCAGGTGAGT GACCTGGAGG GAGGGGGTCA CCCCTAAAAA CAGGGGTAGT 
      841 GCTAGGACTG AAACCCTCCC TTCTTGATAT CCCACTGGCA AGCTTGAGGA GCCAGGCTGC 
      901 CAGTCGGGAG ATTCGGCCCA GTGTTCCCAC TGGAGAGGGC GGCAAGTGCC CGGGCGATCC 
      961 CCTCACCTGC GTTCGGGAGA TATACCCCCG CCCCCGCCCC GCCAGGAGGG TGAAAAGATG 
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     1021 GCCCCAGGAG CCAGCCGGCT GGGACAAGGC GGAGTGAGAG GACAGGCTGG GGCCAGGGGC 
     1081 GCTGGGCTGT CCCGGGCAGC CCTCCTCCGG GCAAGCCGGA GCAGGGGTGG ATTGGGAGCG 
     1141 CTCGGGGCGG GCCCGCGGTG GCCCCGGGGC GGTGGCGCCC GGCCGGAGAG GGTGGGGCGG 
     1201 AGCAGCCGCC CTGTACTTCC CCTTCGCCGC TAGCTCTACA ACAGCCTGAT TTCCCCGAAA 
     1261 TGACGGCACG CAGCCGGCCA ATGGGCGCCC GCGCGGCTGT CCGGGGGCGG GGCCGGCCAG 
     1321 GGCTGGGGAA TCCCGCTAAG TGTTTGGATT GCTCGGTGGC GCCGCTGCCC TGGCAGAGCT 
     1381 CGCCACTCCT TAGTCGAGGC AAGACGTGCG CCCGAGCCCC GCCGAACCGA GGCCACCCGG 
     1441 AGCCGTGCCC AGTCCACGCC GGCCGTGCCC GGCGGCCTTA AGAACCCGGC AACCTCTGCC 
     1501 TTCTTCCCTC TTCCACTCGG AGTCGCGCTC CGCGCGCCCT CACTGCAGCC CCTGCGTCGC 
     1561 CGGGACCCTC GCGCGCGACC GCCGAATCGC TCCTGCAGCA GAGGTGAGTA CGCCTTTGAG 
     1621 GCGCGGGGCA CCGGCGGCGT CGAATAAAAG GCGCGCGGGG CACCAGGAAG TGGGGGGTCG 
     1681 AAAGCTCCAG GCTGGAGACT CGCCGGCGCG CGGCGTTGCC CGGGCCTCCG CGCGGGCTCC 
     1741 GGGGGGCGCC GGAGGAGCTG CGAGCCGCGG GCCGCGGCGC GGGGAGGGCG GGACGCGGCG 
     1801 TGGACCGCCC ACCCGGACGA GGCTGCCGGC GCCCGGCAGC TTTCGCAGAT CTGCGTGCGC 
     1861 GCAGCCGCCA GGGGCCTGTA GGTGGCCCGC TATGTTCGTC CCGCGCATCC ACACGCCGTG 
     1921 CCGGGGACCG AGTGTCAGCC CACGCGTGGG CGCCCAGTGC TCCCGGCTTT CGGCGGTCCC 
     1981 AGCTCCGCGC CCAGGCGACA GGTTTTGGGC TCCCTGTGCT GGTGGCAAGG GCTGGCTTAC 
     2041 TGCCCAGGTG GCTGGAGGGA ATCGTGACCT ACGGAGACTG CGGGAAGAGG CGCCACAGGT 
     2101 GTTCCTTGGG CCACTTCTCC AGAGGAGGGG AAACCGGGCC GGAAGGGTTA GCGTCCTGGT 
     2161 CTTAGCGTTG TGGGCGCTGT GGCTGTCAGG AAGGCGTAGA ATGGATTCAG GGGGGCGGGA 
     2221 GGGGGCTGTT CAGGGTGACG GCTAGCCCTT TGCTAGCTAG TGGTTACAAC TCAAGTCAAG 
     2281 GGAATTTCTT CTTGGCATCA AGCAAAAGAA GTCCCTCCCT TCCCAAAGGA TTTGAATTTT 
     2341 GAGCGAAAAG TTCTGAAATT AGGGTATCTG TGCATTTTGT CTCTTTTCCT GCATATGAAT 
     2401 CCTGAAGCCA TCACTTGCAT GCCTGTCTCC TCCAGAGACT GGCTGGGAGG GGCTGAAGGA 
     2461 AGGGGCAAAA GCATTTTTGC CTAAGATGCT GAAAAAATTT GGAGAGCAGT TTTATTCCAG 
     2521 CGCAGCTCCC CTCCGCACTG AGTGTAGTAC CTAGCAGCTG GCTGAGGTGA GGGGAGGGTA 
     2581 ACTAAGTGAC CTCGGGTGGG GCAGGTCACT GCCCAGGTAC TGTTCAACAG ATTCCAGACT 
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     2641 GGAGCCTCTG TGTTCTCTTT ACAGCCAACA TGCCCATCAC TCGGATGCGC ATGAGACCCT 
     2701 GGCTAGAGAT GCAGATTAAT TCCAACCAAA TCCCGGGGCT CATCTGGATT AATAAAGTGA 
     2761 GTGTAACTCT TTGGGTTTTC CTGCCACTGT TTTAACCCAT GTACTTCTGG AGGGACCAAA 
     2821 GCTTCAGATG CAGCTCAAAA AGGGAAGTGA TAACGGGACA AGCAGGTGTT TCTCCCAGTG 
     2881 GGTCCTGCAT GCAGGGAGTG TGCACGGCCC AGCCTGGGCC TCACTTGCAT GACTCCTGCC 
     2941 TTCTTCCCTT CTTGAGGTAG GGCACCCACC TGAAGGCACT TCCAGTTTCC AGCAGCAAGA 
     3001 CTTTCCAGCA TCTGCAGAGC TGGAGTTCTG CTCTCCTCTA AGCGAGACCC TTACAAACAT 
     3061 ACACAGCACT CTGCAGGGCT CCAATCGAAC AAATAGAAGA CTGAGAAGTG GATGCTGCTG 
     3121 GGCAGAAACG TGCCTGGCTT AGCAGAGGAC AAACGAGTTA ATCTTGCACC AGTCACTCTG 
     3181 GCCCAAGAAG CCTATAGCTG GTGCACTTGG GGCAACATAG ACCCTATAGA CTTAGTAGCA 
     3241 ATGATAGTAT TCATAATAAT AGCTAATGCT TACTGAACAC TCCCTGTGTG CCTGGCACCT 
     3301 GCTAAGTATG TTATTTACAT TGTGTCATTT AATCCTCGCA GTAGTCCTGT GGGTTAGATC 
     3361 TTACTAATGT CATCATTTTC AGATAAGTAA ACAGAGGCAC TGAGAGGTAG ATCATAAGAT 
     3421 CACACAAAAA GTGATGAAGC CAAGATTTGA ACTTGAACGG TCTGACTCAG AAATCTTTAC 
     3481 TGTTAACCAT AAGTGATATA ATAACAGTAA GACCTTAGAC TTCATATTTG TCACTGTGTC 
     3541 CCTACACATC CTCTGGTTTT TAATCCTCAA AATTTTGTTG GATATGTTTT CTCATTTCCG 
     3601 AGAAGAGAAA ACTGAGGGGC AAAGAGATAC AGTGACAATG CCAGGGTTAC ACAGTGTTCA 
     3661 CCATCCAAGT CTAGCCCAGA GCTCCCTCAG TGGTATGACC AGGACCCCCT GTGTAAGAGC 
     3721 CCATGCTCCC AGGTGTCCTG AGGAGTCCTT TCTAATGGAA GAAGTTCTTA CTTCCATGTG 
     3781 GGTGCTTACA AGCCAGAGAG AAACATCCCA GAGCTTCAAA ACCAGGGCTT TGGGGGAGGG 
     3841 TGCCCTGTGT GGGTCCTAGC ACATGTGTAA CAGGCAGAGG GAGGTCTTTG TGAGCTAATA 
     3901 ATGCTGCAGC TCATCCAAAC TAGGTGTCCC TCCTGAGAGA TCCAGAGTGG TCTGTTTAAG 
     3961 CCAGCCTCAA GATGGGTGTC CAAGCCAGAT GTCAGGGGAA AAAAGGGGAA GTCAGCCTTT 
     4021 TCTCAGACCT GTCTGGCTGG GCAGGCCTGG GTCTCAGACT CAGCCCCAAA GTCTGTGGTC 
     4081 TCTGACCTGA CACAGCCTTA TGTGTATGTG TGTATTGTTC AGGAGGAGAT GATCTTCCAG 
     4141 ATCCCATGGA AGCATGCTGC CAAGCATGGC TGGGACATCA ACAAGGATGC CTGTTTGTTC 
     4201 CGGAGCTGGG CCATTCACAC AGGTGTGTGC CTGGGACTCA GGCCTAGGAA GCCCAGGGTA 
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     4261 GAGACAAGAG GAGGCACTCA CGTTAACACA GAGGCTCTTC ACTGGGGTCC CTGAGCTCCC 
     4321 TGAGACAACA TGCAGAATTA CTGGGAAGAG GGGCTGGTGG CAGACTTGTG TTTCTGGAGA 
     4381 AGAGAGTCGA TCATCTCAGC AAATTCTCAA AGGGAAAAGC CAAGATCTTA GAAAGTGTGT 
     4441 GGCTTCAGGG GGTTTGTGGC TAGATGAAAG TTCTCCCTGG CAAAAGCATC TGTGAAAAGC 
     4501 AGCTGTAAGC CAGGGCACTG AAAGAGACCC AGGTCTGCCT TTTTCTTCGT GTTGACCAAG 
     4561 GCCCTTGGTC CAAGCCTCAT GTGGTTGGTG GCCTCCTTTA TCCTTGAGAG ATGGAGCTCT 
     4621 AGGCCCATCT CAGAACAGTC AGCCCACCCA TTTAGTAACT GTTCTCTGCT GCCCAGTCTG 
     4681 TGCCCACTCT ACCCTCTGGC TGCTGATAGC CCAAGGAGGA AGACTGGGCA TAGTCTGAGA 
     4741 CACAGATAGT ACACTTTGGG GATATGGGGA CTCTAGTGCT TCTGGCTGGG CCCTTCACTG 
     4801 AGGCCCGCTA GATGTGTTTA AGCCAAGCCT GGGCATTTGA GAAGGCCCAG GGCCTAGGAC 
     4861 CTGCAGAGTG TCACCGGGAG TACCTGCTGG TTTGACCACT GTGGCTCTCT GGTAGCATAA 
     4921 GAGGTCAGGG GTACCTTGCC TTCCTCCTTC AGGCCAGGGG CAGCTGAGGA TCCCTACCCA 
     4981 TGGCCCTGAC GATCCTCTTT TTTCTCCTGC CCTCTAGGCC GATACAAAGC AGGGGAAAAG 
     5041 GAGCCAGATC CCAAGACGTG GAAGGCCAAC TTTCGCTGTG CCATGAACTC CCTGCCAGAT 
     5101 ATCGAGGAGG TGAAAGACCA GAGCAGGAAC AAGGGCAGCT CAGCTGTGCG AGTGTACCGG 
     5161 ATGCTTCCAC CTCTCACCAA GAACCAGAGA AAAGGTATCC AAGGACTCTG GGTCCTTGGG 
     5221 AAGCCCTCAG GGAGGGAGGG TAGAAGGAGG TCAGCTGGGG CTGGAGAGCC TGCACCAAGG 
     5281 CTGACAGCCC GTCTGCCCCA CAGAAAGAAA GTCGAAGTCC AGCCGAGATG CTAAGAGCAA 
     5341 GGCCAAGAGG AAGGTGAGTG TGGTCCTAAG CAGCCAGGCC TTTGGTCACC TGTGGGCCAG 
     5401 GGTGAGCAGT GGAAGAAATG CTAAGGTGGG CCTGGGCCTA AGCTGCTTTC TCCCTCGACA 
     5461 GTCATGTGGG GATTCCAGCC CTGATACCTT CTCTGATGGA CTCAGCAGCT CCACTCTGCC 
     5521 TGATGACCAC AGCAGCTACA CAGTTCCAGG CTACATGCAG GACTTGGAGG TGGAGCAGGC 
     5581 CCTGACTCCA GGTGAGCTGG TCCAGGTCTG GCAGGAGACC CCACAGGTCA GTGGGATGAC 
     5641 TCTTTCTCTT GGAGGCATGG TGCTGGCACA TGGTGGCCCA TTAGTGCAGG CTGCAGGGTT 
     5701 GGTCGGAGGG CGCTCGATGT CTTGCAAACT AAGAAAGCAC ACAACCTTGA CCTGTGGCTT 
     5761 CTGCTGTTCC CCAGCACTGT CGCCATGTGC TGTCAGCAGC ACTCTCCCCG ACTGGCACAT 
     5821 CCCAGTGGAA GTTGTGCCGG ACAGCACCAG TGATCTGTAC AACTTCCAGG TGTCACCCAT 
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     5881 GCCCTCCACC TCTGAAGGTT GGTGCTCCTG GGGCCTGGCC TGCCTGCTTG ACTGTCTGGG 
     5941 TCCTGTGAAG GGCTTCCTGA GAGAGAAAAG ATGATCAGAA CTCCACCTGG CACTGAATTG 
     6001 ATTGAGTTGG GCATTGCCCA GTCTTAGCCA CCATAGGGGG AGGCAAGCGA CGGGGACACT 
     6061 AGGAAGGCAG TTCAGAGTGG GCTGCAGTAC AGTGGGGGCT GGTGAGAGGA GGGAAGGGGG 
     6121 CCAGGGGCTG CATTTTGGGG TGCTGGTTCT CCTTCCTCCT CTGTAGCCCA GCATCTGAGG 
     6181 GTGAGGAAGG AAGTAGGGTA GGGGTGGGAA GCGGCGTGGC TTCAGGGTTT GAGAGGCTGA 
     6241 GTCACCAGGC CAGGGTCCTG TTCTGGAATC TCTATGGCAG ATAGGTCCAC CGGGAGGGTG 
     6301 TGTGTGTGTG TGTGTGTGTC AGAGAGACAG AGAGACAGAG AAAGGGCAGG GGGATCTGGT 
     6361 GGGCTGGAAC TGGAACTGCA GGGTGAGTGT GGCTGACTGC CAGCCAACCT CTCTGCTTTC 
     6421 CCCATCCACA CGTACAACAG ATGAGGATGA GGAAGGGAAA TTACCTGAGG ACATCATGAA 
     6481 GGTAAAGCCC CTTCCTACCT GGGCACTCTT GAAGTGACCG TTTCTCAGTG AGGAGAGAGA 
     6541 ACCAGTGAAG CTTCCAAATC AGAGGATGGG TAGCTGCTGT TGTCACCTGG CTGCTTGCAT 
     6601 TGTCCCACAA GTGCCACATT CACGTGGCTT GACTGGTGGG AAAGCCACCA TGGGAAGGGA 
     6661 AGGCAGGTGG GAGGCCTGGC CTCTGACAGG CCGTCCTGAA GCAAGCCTTG GGGCATCAGA 
     6721 CAGCTCTGTG AGTCAGGCAC TATCAGCGAT GGGTCCCTGG CCTGCATCCT CTGCCCCAAC 
     6781 ATGCCCCAGC CCTGCTAGTT CGGGAAATGC ACATCAGGCT TCAATAATCA GCCTTTAGGA 
     6841 TCCGTTAATA TGATGATGGC TTTATAGAAA AAGTTAGCAA ATTATCCTCC AGGTTTTTTT 
     6901 TTCTGCTTCA GTTTTGAAAG TGAATATAGT TTTTGCAGCC GGGGGCAGTG GCTCATGCCT 
     6961 GTAATCCCAG CACTTTGGAA GGCGAAGGTG GGTGGATCAC CTGAGGTCAG GAGTTTGAGA 
     7021 CCAGCCTGAC TAACATGGTG AAACCCATCT CTACCAAAAA TATAAAAATT AGCTGGGCCT 
     7081 GGTGGCGCAT GCCTGTAATC CCAGCTACTC TGAAGGCTGA GGCAGGAGAA TCGCTTGAAC 
     7141 CTGAGAGGCG GAGGTTGCAG TGAGCTGAGA TTGTGTCATT GCACTCCAGC CTGGGCAACA 
     7201 AGAGCAAAAC TCCATTTCAA AAAAAAGTTT TTGCAGTAGT TGTACGCCAG CTGTTCCATT 
     7261 AGCCCAAAAA ATTGAGACAT GGATGTCGTT CCTTATCTCT AGCTTTTCTA GTCATCTTTT 
     7321 CTTGATTTAT TATGCTAACC TTTGTTTTAA GCCACATTCC CTCTTACTAT GTCCTTACAC 
     7381 AGTTGAGAGG GAAGTCGTGG AGATGCTATA CCAGAGAGTG GGTGTGAGAG GGGTGGGAAA 
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     7441 ATGAATTGAG GACCAGTGCC AACATGCATT TCTGCCTCCT CCCTCCCGGG CCCTTGTCCT 
     7501 GACTGCAGTG CACTTCTGCA TCCTATCTGA GATTGTGAAA ATGGCCAAGG GTGTGATACT 
     7561 GGCTGAGAGG AGCTGGCTCA TTGAGGGCAG GGCCACAGGG TGAGTCTGCA CTGGAAGGGA 
     7621 GTTGATAGCC TCTTGCTCTT CTGTCCCCAG CTCTTGGAGC AGTCGGAGTG GCAGCCAACA 
     7681 AACGTGGATG GGAAGGGGTA CCTACTCAAT GAACCTGGAG TCCAGCCCAC CTCTGTCTAT 
     7741 GGAGACTTTA GCTGTAAGGA GGAGCCAGAA ATTGACAGCC CAGGGGGTAA GAAGGCCCTG 
     7801 GATCCTTATG GCTTCTTAGA TGAGGGAGAA CCACGTAGGG ATGGAGAAAG CTTGGGGGCA 
     7861 GGGCCAGGGA GCAGGGCGGT AAAGCATCTG GGGTACTGAC ACATTGTGAA TTAGCTACGG 
     7921 CTGCCATGCC TTAAGGTTTG CCTGAAGCTG AGTGGATGTT TACTGCTGTG CTGGGAAGAG 
     7981 CAGAGGCCAT GTCTATGGCC TTCAGGGGTA GGGGGAAGCA CACCTGATGC CACCGTCCCC 
     8041 TACCCTCATA CAACCTTCTT CACATCTTCT AGGGGATATT GGGCTGAGTC TACAGCGTGT 
     8101 CTTCACAGAT CTGAAGAACA TGGATGCCAC CTGGCTGGAC AGCCTGCTGA CCCCAGTCCG 
     8161 GTTGCCCTCC ATCCAGGCCA TTCCCTGTGC ACCGTAGCAG GGCCCCTGGG CCCCTCTTAT 
     8221 TCCTCTAGGC AAGCAGGACC TGGCATCATG GTGGATATGG TGCAGAGAAG CTGGACTTCT 
     8281 GTGGGCCCCT CAACAGCCAA GTGTGACCCC ACTGCCAAGT GGGGATGGGG CCTCCCTCCT 
     8341 TGGGTCATTG ACCTCTCAGG GCCTGGCAGG CCAGTGTCTG GGTTTTTCTT GTGGTGTAAA 
     8401 GCTGGCCCTG CCTCCTGGGA AGATGAGGTT CTGAGACCAG TGTATCAGGT CAGGGACTTG 
     8461 GACAGGAGTC AGTGTCTGGC TTTTTCCTCT GAGCCCAGCT GCCTGGAGAG GGTCTCGCTG 
     8521 TCACTGGCTG GCTCCTAGGG GAACAGACCA GTGACCCCAG AAAAGCATAA CACCAATCCC 
     8581 AGGGCTGGCT CTGCACTAAG AGAAAATTGC ACTAAATGAA TCTCGTTCCC AAAGAACTAC 
     8641 CCCCTTTTCA GCTGAGCCCT GGGGACTGTT CCAAAGCCAG TGAAATGTGA AGGAAAGTGG 
     8701 GGTCCTTCGG GGCGATGCTC CCTCAGCCTC AGAGGAGCTC TACCCTGCTC CCTGCTTTGG 
     8761 CTGAGGGGCT TGGGAAAAAA ACTTGGCACT TTTTCGTGTG GATCTTGCCA CATTTCTGAT 
     8821 CAGAGGTGTA CACTAACATT TCCCCCGAGC TCTTGGCCTT TGCATTTATT TATACAGTGC 
     8881 CTTGCTCGGC GCCCACCACC CCCTCAAGCC CCAGCAGCCC TCAACAGGCC CAGGGAGGGA 
     8941 AGTGTGAGCG CCTTGGTATG ACTTAAAATT GGAAATGTCA TCTAACCATT AAGTCATGTG 
     9001 TGAACACATA AGGACGTGTG TAAATATGTA CATTTGTCTT TTTATAAAAA GTAAATTGTT 
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     9061 TATAAGGGGT GTGGCCTTTT TAGAGAGAAA TTTAACTTGT AGATGATTTT ACTTTTTATG 
     9121 GAAACACTGA TGGACTTATT ATTGGCATCC CGCCTGAACT TGACTTTGGG GTGAACAGGG 
     9181 ACATGCATCT ATTATAAAAT CCTTTCGGCC AGGCGCGGTG GCTCACACCT GTAATCCCAG 
     9241 CACTTTGGGA GGCCGAGATG GGTGGATCAC CTGAGGTCAG GAGTTCGAGA CCAGCCTGGT 
     9301 GAAACTCCAT TTCTACTAAA AATGCAAAAA TTAGCTGGGC GTGGTTGCGG GTGCTTGTAA 
     9361 TCCCAGCTAC TCAGGAGGCT GAGGCAAGAG AATCGCTTGA ACCTGGGAGG TGGAGGTTGC 
     9421 AGTGAGCCGA GAACATGCCA TTGCACTCCA GCCCGGGCAC CAAAAAAAAA AAAAAAAAAA 
     9481 AAAACCTTTC ATTTGGCCGG GCATGGTGGC TTATGCCTGT AATCCTGGCA CTTTGGGAGG 
     9541 CCAAGGTGGG CAGATCACCT GAGGTCAGGA GTTTGAGACC AGCCTGGCCA ACATGGTGAA 
     9601 ACCTCATCTC TACTAAAAAT ACAAAAATTA GGCCGGGCAC GGTGGCTCAC GCCTGTAATC 
     9661 CCAGCACTTT GGGAGGCAGA GGCGGGCGGA TCACGAGGTC AGGAGATCAA GACCATCCTG 
     9721 GCTAACACGG TGAAACCCCG TCTCTACTAA AAATATAAAA AATTAGCCGG GCCTAGTGGC 
     9781 GGGTGCCTGT AGTCCCAGCT ACTCGGGAGG CTGAGGCAGG AGAATGGCAT GAACCCCGGA 
     9841 GGCAGAGCTT GCAGTGAGCC GAGATTGCAC CACTGCACTA CAGCCTGGGC GACAGAGCGA 
     9901 GACTCCGTCT CAAAAAAAAA AAAAAAAATT AGCCGGGCCT GGTGGCGGGC GCCTGTAATC 
     9961 CCAGCTACTG TGGAGGCTGA AGCACAAGAA TCACTTGAAC CCGGGAGATG GAGGTTGCAG 
    10021 TGAGCTGAGA CTGTGCCACT GCACTCCAGC CTGGGTGACA AGAGTGAGAC TTTGTCTCAA 
    10081 AAAAAAAAAA ATCCTTTTGT TTATGTTCAC ATAGACAATG GCAGAAGGAG GGGACATTCC 
    10141 TGTCATAGGA ACATGCTTAT ATAAACATAG TCACCTGTCC TTGACTATCA CCAGGGCTGT 
    10201 CAGTTGATTC TGGGCTCCTG GGGCCCAAGG AGTGTTAAGT TTTGAGGCAT GTGCCATAGG 
    10261 TGATGTGTCC TGCTAACACA CAGATGCTGC TCCAAAAAGT CAGTTGATAT GACACAGTCA 
    10321 CAGACAGAAC AGTCAGCAGC CCAAGAAAGG TCCTCACGGC TGCTGTGCTG GGTAGCACTT 
    10381 GCCATCCAGT TTCTAGAGTG ATGAAATGCT CTGTCTGTAC CGTTCAATAC AGTAGGCACT 
    10441 GGCACTAGCC ACATGTGCCA GCTAAGCACT TGAAATGTGG CCAGTGCAAT AAGGAATTGA 
    10501 ACTTTTAATT GCATTTAATA AACTGTATGT AAATAGTCAC ATGTGGTCAG TGGTTACCAT 
    10561 ATTGAACAGT GCAGGTAGAT ACTGGACTGG GGGCAGATCT GAGGGAGAGG GGTTTGAGTA 
    10621 GTGGGAGGAC ACTGGGGATA GGGGCTTGGG GCTATTTACC TGCCATTTTG AGTAGTTTGC 
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    10681 TATTTTAGCA GCCAACAATA ACTATTGGTG CTGAATACCA GCCCTGCAGT GTAGCATGAG 
    10741 ACAGGTCCAT GCACACATGC ATTAGGAAAA CACCTTCATG AAGCAGGATT CTGCCTGGGC 
    10801 TGATGCACAC AACCTCTATG GAGGGTAAAC AGTGTTTCTG AAGACCGTAG TTTGGGAACC 
    10861 CCTGACATAT GACAATGCCC CCTTAGATAA GCTCAAGTTA CAGGAATGTC TGAGGGTGGA 
    10921 AGGTGTGGAT ATGTGCTTTT CCTGTCTCCC TCTTCAGTGT CTGGCCATGG GGCATAAACA 
    10981 CTACCCAGCA GTAGGTAGGC TGGCCAAGAG AAGCCAGCTT GCATCACCAG CATCATCTAG 
    11041 GGAATGGAAT CATGGCAGTA ATACGTTGCT TAGGAAACAA AAGCTCTATG GACACATCTT 
    11101 CCACCTTCTC AGTCCCAGAA ACCATATGTA CTGTGACCCC GCTCACTAGG CCCAGCCCTC 
    11161 GGGAAGAGTG TGGGCCCTTG AAAAGGGAAG ACTGAGTGAG AAAATGATGA GAAAACTACA 
    11221 AAATGGGCAG AGGTCAGTCT GACACATTCA TTCTCTGTCA AGCTCAGGAA GTACTGGTCC 
    11281 CTGATCTTGG AGATGCTGTG TGAGTGGCAG GGGGACTCCT GCTGGGTAAA TATTCTATAT 
    11341 GTGGATGCCT GGACAGGCCC CTATCCCAGG CCCTGCTTGT CAGAAGCTCC CCTTGGGCCG 
    11401 AGCGCGGTGG CTCACACTTG TAATCTTGGC ACTTTGGGAG GCCGAGGCAG GTGGATTGCC 
    11461 TGAGTTCAGG AGTTCAAAAC CAGGCTGGGC AACATGGTGA AACCCTGTCT CTACTAAAAA 
    11521 AAAACTAACC AGGCGTGGTG GTGCATGCCT GTAATTCCAG CTACTAGGGA GGCTGAGGCA 
    11581 GGCCAATCAC TTGAACCCAG GAGGTGGAGG TTGCAGTGAG CTGAGATCAC GCCACTGCAC 
    11641 TCTAGCCTGG GCAACAGAGC GAGACTCTGT CTCAAAAAAA AAAAAAAAAA AGAAGTTCTA 
    11701 CTTGGAAGCT CCACTTGGAT TTCTCAAGAA TAGCTTCACC TGGGAACAGA GGAATAGACA 
    11761 GGATGGACTT TTCCAGCTCC TTCAGGGACC AGCCCTTTTT AAGATTTGGA TTGAGGTGGC 
    11821 TAGCCACCTG TGGCTTCCAT CTGGGTTCTC CTAGTGGGTG ATGGCAGGTG GTGCAGAGCA 
    11881 AGGTAGAGTG GACTGACGGG AGGAAAGTGA TACCA 
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Appendix III 
Expression profile of IRF-1 of Cases 12 to 32 on tumor tissue on lanes 4 to 14, 100bp 
marker in lane 1 and negative and positive control respectively. PCR samples were 
amplified on a Multi Gene II gradient thermal cycler (Labnet, UK). All cases were 
tested at 35 PCR cycles. The arrow indicates expression of IRF-1 at 187 bp. 
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Appendix III 
Expression profile of IRF-1 of Cases 33 to 44 on tumor tissue on lanes 4 to 14, 100bp 
marker in lane 1 and negative and positive control respectively. PCR samples were 
amplified on a Multi Gene II gradient thermal cycler (Labnet, UK). All cases were 
tested at 35 PCR cycles. The arrow indicates expression of IRF-1 at 187 bp. 
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Appendix III 
Expression profile of IRF-1 of Cases 56 to 66 on tumor tissue on lanes 4 to 14, 100bp 
marker in lane 1 and negative and positive control respectively. PCR samples were 
amplified on a Multi Gene II gradient thermal cycler (Labnet, UK). All cases were 
tested at 35 PCR cycles. The arrow indicates expression of IRF-1 at 187 bp. 
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Appendix III 
Expression profile of IRF-1 of Cases 78 to 99 on tumor tissue on lanes 4 to 14, 100bp 
marker in lane 1 and negative and positive control respectively. PCR samples were 
amplified on a Multi Gene II gradient thermal cycler (Labnet, UK). All cases were 
tested at 35 PCR cycles. The arrow indicates expression of IRF-1 at 187 bp. 
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Appendix III 
Expression profile of IRF-1 of Cases 100, 101, 91, 92,93 and 94 on tumor tissue on 
lanes 4 to 14, 100bp marker in lane 1 and negative and positive control respectively. 
PCR samples were amplified on a Multi Gene II gradient thermal cycler (Labnet, 
UK). All cases were tested at 35 PCR cycles. The arrow indicates expression of IRF-1 
at 187 bp. 
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Appendix IV 
 
ABI 377 Sequencer (Adapted from Azco Biotech, Inc. catalogue) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ABI 377 Sequencer 
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Appendix V (a) 
Samples with Loss of heterozygosity: 
Allele sizes were determined by electrophoresis of PCR products in 6% denaturing 
polyacrylamide gels and were compared to ROX 500 size standards (Applied 
Biosystems, Foster City, CA), using an automated sequencer (ABI 377), according to 
the manufacturer’s instructions (Applied Biosystems). Fluorescent signals from the 
different size alleles were recorded and analyzed using GENOTYPER version 2.1 and 
GENESCAN version 3.1 software (Applied Biosystems). 
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Appendix V (a) 
Samples with Loss of heterozygosity continued: 
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Appendix V (a) 
Samples with Loss of heterozygosity continued: 
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Appendix V (b) 
Samples with no loss of heterozygosity: 
Allele sizes were determined by electrophoresis of PCR products in 6% denaturing 
polyacrylamide gels and were compared to ROX 500 size standards (Applied 
Biosystems, Foster City, CA), using an automated sequencer (ABI 377), according to 
the manufacturer’s instructions (Applied Biosystems). Fluorescent signals from the 
different size alleles were recorded and analyzed using GENOTYPER version 2.1 and 
GENESCAN version 3.1 software (Applied Biosystems). 
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Appendix V (b) 
Samples with no loss of heterozygosity continued: 
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Appendix V (b) 
Non Informative samples: 
 
Allele sizes were determined by electrophoresis of PCR products in 6% denaturing 
polyacrylamide gels and were compared to ROX 500 size standards (Applied 
Biosystems, Foster City, CA), using an automated sequencer (ABI 377), according to 
the manufacturer’s instructions (Applied Biosystems). Fluorescent signals from the 
different size alleles were recorded and analyzed using GENOTYPER version 2.1 and 
GENESCAN version 3.1 software (Applied Biosystems). 
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Appendix V (b) 
Non Informative samples continued: 
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Appendix VI 
Table representing Clinical data (identity of patients with held) of 101 samples: 
Sample number, age, ER status, PR status, HER2/neu, Triple negative cases. 
Sample 
no. 
Age Early 
stage 
tumor 
(1) 
Late 
stage 
tumor 
(2) 
ER +ve 
 (1) 
ER 
-ve 
(2) 
PR 
+ve 
(1) 
PR -ve 
(2) 
Expressed 
or not ( +ve 
or -ve) 
HER2 
(+ve) 
(1) 
Equivoeal  
(2) 
HER2 
( -ve) 
(3) 
TNBC 
(4) 
1 56y 1   1     2 1 1       
2 80y   2 1     2 1     3   
3 58y   2 1     2 1 1       
4 44y 1     2   2 1   2     
5 38y   2   2   2 1     3 4 
6 57y 1     2   2 1 1       
7 57y   2   2   2 1 1       
8 60y   2 1     2 1     3   
9 48y       2   2 1 1       
10 59y     1     2 1     3   
11 55y     1     2 1 1       
12 64y   2 1     2 1     3   
13 36y     1     2 1     3   
14 43y   2   2   2 1     3 4 
15 44y     1     2 1     3   
16 46y       2   2 1     3 4 
17 45y   2 1     2 1     3   
18 35y     1     2 1     3   
19 40y       2   2 1     3 4 
20 29y     1   1   2   2     
21 76y   2 1     2 1 1       
22 44y       2   2 1 1       
23 45y 1   1     2 1     3   
24 40y   2   2   2 1     3 4 
25 78y   2 1     2 1     3   
26 55y   2   2   2 1 1       
27 22y 1   1     2 1 1       
28 39y 1     2   2 1 1       
29 38y   2 1     2 1 1       
30 57y 1     2   2 1     3 4 
31 51y 1     2   2 1     3 4 
32 49y 1     2   2 1     3 4 
33 49y 1   1     2 1     3   
34 76y 1     2   2 1   2     
35 66y 1   1     2 1     3   
36 65y 1     2   2 1 1       
37 48y 1   1     2 1 1       
38 38y   2   2   2 1 1       
39 41y 1   1   1   2 1       
40 36y 1     2   2 2     3 4 
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41 50y 1     2   2 1   2     
42 58y 1 2 1     2 1     3   
43 64y 1     2   2 1     3 4 
44 39y 1     2   2 1     3 4 
45 61y   2   2   2 1     3 4 
46 65y 1     2   2 1     3 4 
47 55y   2   2   2 1     3 4 
48 52y   2   2   2 1   2     
49 55y   2   2   2 1     3 4 
50 51y   2 1     2 1     3   
51 56y     1     2 1     3   
52 45y 1     2   2 1     3 4 
53 52y 1     2   2 1     3 4 
54 55y     1     2 1 1       
55 36y       2   2 1 1       
56 54y       2   2 1     3 4 
57 30y     1     2 1 1       
58 48y     1     2 1     3   
59 69y     1     2 1   2     
60 53y     1     2 1     3   
61 31y     1     2 1 1       
62 31y 1   1     2 1   2     
63 43y     1     2 1   2     
64 64y   2 1     2 1     3   
65 29y     1     2 1 1       
66 69y 1     2   2 1 1       
67 40y     1     2 1   2     
68 39y 1     2   2 1     3 4 
69 58y   2   2   2 1 1       
70 63y       2   2 1     3 4 
71 23y       2   2 1     3 4 
72 59y     1     2 1     3   
73 54y     1     2 1   2     
74 39y       2   2 1 1       
75 64y     1     2 1     3   
76 57y     1   1   2     3   
77 48y     1     2 1     3   
78 53y     1     2 1 1       
79 36y       2   2 1 1       
80 44y     1     2 1     3   
81 61y     1     2 1         
82 53y     1     2 1         
83 76y     1     2 1 1       
84 72y     1     2 1     3   
85 61y       2   2 1     3 4 
86 63y     1     2 1 1       
87 69y       2   2 1     3 4 
88 70y     1     2 1     3   
89 56y     1     2 1     3   
90 50y       2   2 1     3 4 
91 79y     1     2 1   2     
92 37y       2   2 1     3 4 
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93 60y     1     2 1     3   
94 60y     1     2 1     3   
95 54y     1     2 1   2     
96 63y     1     2 1     3   
97 53y     1     2 1     3   
98 56y       2   2 1     3 4 
99 73y       2   2 1     3 4 
100 68y       2   2 1   2     
101 50y     1     2 1 1       
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Appendix VI 
Table: Representing data of 101 samples:Age,tumor stage, ER and PR (-ve or +ve) 
Sample 
no. 
Age Young 
 (≤ 50) 
Old 
 (>50) 
Early 
stage 
tumor (1) 
Late stage 
tumor (2) 
ER Positive 
(1) 
ER Negative 
(2) 
PR Positive 
(1) 
PR Negative (2) 
1 56y   2 1   1     2 
2 80y   2   2 1     2 
3 58y   2   2 1     2 
4 44y 1   1     2   2 
5 38y 1     2   2   2 
6 57y   2 1     2   2 
7 57y   2   2   2   2 
8 60y   2   2 1     2 
9 48y 1         2   2 
10 59y   2     1     2 
11 55y   2     1     2 
12 64y   2   2 1     2 
13 36y 1       1     2 
14 43y 1     2   2   2 
15 44y 1       1     2 
16 46y 1         2   2 
17 45y 1     2 1     2 
18 35y 1       1     2 
19 40y 1         2   2 
20 29y 1       1   1   
21 76y   2   2 1     2 
22 44y 1         2   2 
23 45y 1   1   1     2 
24 40y 1     2   2   2 
25 78y   2   2 1     2 
26 55y   2   2   2   2 
27 22y 1   1   1     2 
28 39y 1   1     2   2 
29 38y 1     2 1     2 
30 57y   2 1     2   2 
31 51y   2 1     2   2 
32 49y 1   1     2   2 
33 49y 1   1   1     2 
34 76y   2 1     2   2 
35 66y   2 1   1     2 
36 65y   2 1     2   2 
37 48y 1   1   1     2 
38 38y 1     2   2   2 
39 41y 1   1   1   1   
40 36y 1   1     2   2 
41 50y 1   1     2   2 
42 58y   2 1 2 1     2 
43 64y   2 1     2   2 
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44 39y 1   1     2   2 
45 61y   2   2   2   2 
46 65y   2 1     2   2 
47 55y   2   2   2   2 
48 52y   2   2   2   2 
49 55y   2   2   2   2 
50 51y   2   2 1     2 
51 56y   2     1     2 
52 45y   2 1     2   2 
53 52y 1   1     2   2 
54 55y   2     1     2 
55 36y   2       2   2 
56 54y 1         2   2 
57 30y   2     1     2 
58 48y 1       1     2 
59 69y 1       1     2 
60 53y   2     1     2 
61 31y   2     1     2 
62 31y 1   1   1     2 
63 43y 1       1     2 
64 64y 1     2 1     2 
65 29y   2     1     2 
66 69y 1   1     2   2 
67 40y   2     1     2 
68 39y 1   1     2   2 
69 58y 1     2   2   2 
70 63y   2       2   2 
71 23y   2       2   2 
72 59y 1       1     2 
73 54y   2     1     2 
74 39y   2       2   2 
75 64y 1       1     2 
76 57y   2     1   1   
77 48y   2     1     2 
78 53y 1       1     2 
79 36y   2       2   2 
80 44y 1       1     2 
81 61y 1       1     2 
82 53y   2     1     2 
83 76y   2     1     2 
84 72y   2     1     2 
85 61y   2       2   2 
86 63y   2     1     2 
87 69y   2       2   2 
88 70y   2     1     2 
89 56y   2     1     2 
90 50y   2       2   2 
91 79y 1       1     2 
92 37y   2       2   2 
93 60y 1       1     2 
94 60y   2     1     2 
95 54y   2     1     2 
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96 63y   2     1     2 
97 53y   2     1     2 
98 56y   2       2   2 
99 73y   2       2   2 
100 68y   2       2   2 
101 50y   2     1     2 
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Appendix VII 
Table: Representing data of 101 samples: LOH(NI=non informative, ND=non 
detectable), gene expression of AKT1, AKT2, PIK3, FGFR, PTEN, HER2, ER 
Sample 
no. 
LOH 
NORMAL 
AND 
TUMOR HER2 AKT1 AKT2 ER PIK3CA FGFR2 PTEN Number of genes altered 
1 LOH 4.89   2.17 1.71 4.89 1.31 1.15 4 
2 NO LOH - - - - - - - - 
3 NO LOH - - - - - - - - 
4 NI - - - - - - - - 
5 LOH - - - - - - - - 
6 NO LOH - - - - - - - - 
7 NI - - - - - - - - 
8 NI 1.4 2.4 1.76 0.55 1.4 1.75 1.37 4 
9 NO LOH - - - - - - - - 
10 NO LOH - - - - - - - - 
11 LOH - - - - - - - - 
12 LOH - - - - - - - - 
13 NO LOH - - - - - - - - 
14 LOH - 0.35 1.97 0.27 - - 1.01 4 
15 LOH - 1.59 0.3 - - -   1 
16 NO LOH - - - - - - - - 
17 LOH - - - - - - - - 
18 NO LOH - - - - - - - - 
19 NI - - - - - - - - 
20 NO LOH - 1.5 - - - - - 0 
21 NO LOH - - - - - - - - 
22 NO LOH - - - - - - - - 
23 ND - - - - - - - - 
24 ND - - - - - - - - 
25 ND - - - - - - - - 
26 ND - - - - - - - - 
27 ND - - - - - - - - 
28 LOH - - - - - - - - 
29 LOH 10 2.81 1.39 0.31 - - 1.98 4 high 
30 ND - - - - - - - - 
31 NI 4 - - - - - - 2 
32 NO LOH 4 1.19 0.26 - - - 1.15 5 
33 ND - - - - - - - - 
34 ND - - - - - - - - 
35 LOH 50 1.35 - - - - 0.63 4 high 
36 ND - - - - - - - - 
37 NI 13 1.24 0.56 1.18 - - 0.32 6 high 
38 ND - - - - - - - - 
39 ND - - - - - - - - 
40 NI - - - - - - - - 
41 LOH 2 0.06 - - - - - 2 
42 LOH 2 0.37 - - - - - 2 
43 NI 4   - - - - - 2 
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44 LOH 0.99 2.77 2.05 2.46 0.99 1.69 1.89 4 
45 NO LOH 2 - - - - - - 0 
46 LOH 2 - - - - - - 0 
47 NI 2 - - - - - - 0 
48 NO LOH 2.38 1.34 2.23 0.67 2.38 1.75 1.74 3 
49 NO LOH 1.42 2.02 0.54 0.60 1.42 0.53 0.4 5 
50 LOH 2 1.87 1.52 0.79 - - 0.61 2 
51 LOH 2 - - - - - - 0 
52 NI 2 - - - - - - 0 
53 NO LOH 13 2.19 1.95 0.37 - - 0.67 4 high 
54 LOH 28 - - - - - - 1 
55 NO LOH 10.54 0.94 0.71 0.43 10.54 0.51 - 6 high 
56 LOH 2 1.13 2.04   - - 1.06 1 
57 NI 12 1.46 1.27 0.29 - - 0.64 6 high 
58 LOH 2 - - - - - - 1 
59 LOH 2 - - - - - - 1 
60 NI 2 - - - - - - 1 
61 ND 8.94 1.37 2.02 1.23 8.94 1.31 1.83 5 high 
62 NI 2.6 1.45 1.24 0.76 2.6 1.34 0.53 5 
63 NI 1.28 1.62 1.4 0.69 1.28 - 0.4 6 
64 NI 1.47 2.1 2.22 0.58 1.47 1.9 2.09 4 
65 NI 7.95 2.25 2.72 7.21 7.95 1.78 1.58 5 high 
66 NI 4.39 - - - 4.39 - - 3 
67 LOH 2.47 1.52 1.81 0.47 2.47 2.15 2.57 4 high 
68 ND - - - - - - - - 
69 NO LOH - - - - - - - 1 
70 NI - 0.81 - - - - - 2 
71 LOH 2.24 1.55 2.45 0.34 2.24 1.87 2.24 1 
72 NI - 2.12 - 0.30 - - 0.67 3 high 
73 NO LOH 1.26 2.31 1.49 0.69 1.26 1.27 0.77 5 
74 NI 13.72 1.2 1.4 0.97 13.72 1.18 0.65 7 high 
75 NO LOH - 1.48 0.71 - - - 0.31 3 
76 LOH - - - - - - - - 
77 NO LOH 1.79 2.67 - 1.21 1.79 2.23 2.16 2 
78 NO LOH 4.74 2.18 - 1.43 4.74 1.7 2.14 2 
79 ND 4.94 2.43 - 2.63 4.94 1.98 3.1 5 
80 NI 2.44 2.23 1.87 0.85 2.44 1.84 1.86 1 
81 NI - 2.9 1.24 1.19 - 2.19 1.17 5 high 
82 ND 3.01 1.16 1.63 1.97 - 1.69 2.2 3 
83 ND 12.52 2.66 1.69 0.19 12.52 - 2.96 6 high 
84 ND - 1.64 - - - -   0 
85 NO LOH 1.07 1.5 1.78   1.07 - 1.29 4 
86 ND 1.79 2.36 2.78 0.60 1.79 - 1.75 3 
87 ND - - - 0.00 - -   0 
88 ND - - - - - -   - 
89 ND 2.14 2.12 2.73 0.77 2.14 - 1.68 1 
90 ND 1 1.65 2.45 1.03 1 - 1.63 3 
91 ND 2.66 2.48 1.9 1.01 2.66 2.04 1.84 3 
92 ND - - - - - - - - 
93 ND - - - - - - - - 
94 ND 2.12 2.07 0.8 0.93 2.12 - 2.29 3 
95 ND - - - - - - - - 
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96 ND - - - - - - - - 
97 ND - 0.75 1.37 0.6 - - 0.97 5 
98 ND - 0.57 1.2 - - - 0.66 4 
99 ND - 2.92 - - - - 0.84 3 
100 ND - - - - - - - 1 
101 ND - 2 1.11 - - 0.45 1.35 4 
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